Publications - The Institute of Cancer Research, London

Publications Highlights View all by category

Types of Publications

Journals
Books Chapters
Conference

Journal Articles

Ou, S.-. Gadgeel, S.M. Barlesi, F. Yang, J.C. De Petris, L. Kim, D.-. Govindan, R. Dingemans, A.-. Crino, L. Léna, H. Popat, S. Ahn, J.S. Dansin, E. Mitry, E. Müller, B. Bordogna, W. Balas, B. Morcos, P.N. Shaw, A.T. (2020). Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. Lung cancer, Vol.139, pp. 22-27.

Lim, K.H. Popat, S. (2020). Highlights in lung cancer in 2019. Esmo open, Vol.5 (1), pp. e000676-e000676. show abstract

Felip, E. Ardizzoni, A. Ciuleanu, T. Cobo, M. Laktionov, K. Szilasi, M. Califano, R. Carcereny, E. Griffiths, R. Paz-Ares, L. Duchnowska, R. Garcia, M.A. Isla, D. Jassem, J. Appel, W. Milanowski, J. Van Meerbeeck, J.P. Wolf, J. Li, A. Acevedo, A. Popat, S. (2020). CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. European journal of cancer, Vol.127, pp. 160-172.

Zhang, Y.Z. Brambilla, C. Molyneaux, P.L. Rice, A. Robertus, J.L. Jordan, S. Lim, E. Lang-Lazdunski, L. Begum, S. Dusmet, M. Anikin, V. Beddow, E. Finch, J. Asadi, N. Popat, S. Cookson, W.O. Moffatt, M.F. Nicholson, A.G. (2020). Utility of Nuclear Grading System in Epithelioid Malignant Pleural Mesothelioma in Biopsy-heavy Setting. The american journal of surgical pathology, Vol.44 (3), pp. 347-356.

Minchom, A. Yuan, W. Crespo, M. Gurel, B. Figueiredo, I. Wotherspoon, A. Miranda, S. Riisnaes, R. Ferreira, A. Bertan, C. Pereira, R. Clarke, M. Baker, C. Ang, J.E. Fotiadis, N. Tunariu, N. Carreira, S. Popat, S. O'Brien, M. Banerji, U. de Bono, J. Lopez, J. (2020). Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab. Journal for immunotherapy of cancer, Vol.8 (1), pp. e000713-e000713. show abstract

Remon, J. Passiglia, F. Ahn, M.-. Barlesi, F. Forde, P.M. Garon, E.B. Gettinger, S. Goldberg, S.B. Herbst, R.S. Horn, L. Kubota, K. Lu, S. Mezquita, L. Paz-Ares, L. Popat, S. Schalper, K.A. Skoulidis, F. Reck, M. Adjei, A.A. Scagliotti, G.V. (2020). Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. Journal of thoracic oncology, .

Evison, M. Edwards, J. McDonald, F. Popat, S. (2020). Stage III Non-small Cell Lung Cancer: A UK National Survey of Practice. Clinical oncology, .

Middleton, G. Brock, K. Savage, J. Mant, R. Summers, Y. Connibear, J. Shah, R. Ottensmeier, C. Shaw, P. Lee, S.-. Popat, S. Barrie, C. Barone, G. Billingham, L. (2020). Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. The lancet respiratory medicine, .

Yang, J.C. Schuler, M. Popat, S. Miura, S. Heeke, S. Park, K. Märten, A. Kim, E.S. (2020). Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. Journal of thoracic oncology, Vol.15 (5), pp. 803-815.

Popat, S. Grohé, C. Corral, J. Reck, M. Novello, S. Gottfried, M. Radonjic, D. Kaiser, R. (2020). Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?. Lung cancer, Vol.144, pp. 76-84.

Reck, M. Kerr, K.M. Grohé, C. Manegold, C. Pavlakis, N. Paz-Ares, L. Huber, R.M. Popat, S. Thatcher, N. Park, K. Hilberg, F. Barrueco, J. Kaiser, R. (2019). Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?. Future oncology, Vol.15 (12), pp. 1363-1383.

Tsao, A. Nakano, T. Nowak, A.K. Popat, S. Scagliotti, G.V. Heymach, J. (2019). Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma. Seminars in oncology, Vol.46 (2), pp. 145-154.

Califano, R. Hochmair, M.J. Gridelli, C. Delmonte, A. Garcia Campelo, M.R. Bearz, A. Griesinger, F. Morabito, A. Felip, E. Ghosh, S. Tiseo, M. Haney, J. Kerstein, D. Popat, S. Camidge, D.R. (2019). Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial. Annals of oncology, Vol.30, pp. ii48-ii48.

Planchard, D. Popat, S. Kerr, K. Novello, S. Smit, E.F. Faivre-Finn, C. Mok, T.S. Reck, M. Van Schil, P.E. Hellmann, M.D. Peters, S. (2019). Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Annals of oncology : official journal of the european society for medical oncology, Vol.30 (5), pp. 863-870.

Scagliotti, G.V. Gaafar, R. Nowak, A.K. Nakano, T. van Meerbeeck, J. Popat, S. Vogelzang, N.J. Grosso, F. Aboelhassan, R. Jakopovic, M. Ceresoli, G.L. Taylor, P. Orlandi, F. Fennell, D.A. Novello, S. Scherpereel, A. Kuribayashi, K. Cedres, S. Sørensen, J.B. Pavlakis, N. Reck, M. Velema, D. von Wangenheim, U. Kim, M. Barrueco, J. Tsao, A.S. (2019). Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. The lancet respiratory medicine, Vol.7 (7), pp. 569-580.

Mazieres, J. Drilon, A. Lusque, A. Mhanna, L. Cortot, A.B. Mezquita, L. Thai, A.A. Mascaux, C. Couraud, S. Veillon, R. Van den Heuvel, M. Neal, J. Peled, N. Früh, M. Ng, T.L. Gounant, V. Popat, S. Diebold, J. Sabari, J. Zhu, V.W. Rothschild, S.I. Bironzo, P. Martinez-Marti, A. Curioni-Fontecedro, A. Rosell, R. Lattuca-Truc, M. Wiesweg, M. Besse, B. Solomon, B. Barlesi, F. Schouten, R.D. Wakelee, H. Camidge, D.R. Zalcman, G. Novello, S. Ou, S.I. Milia, J. Gautschi, O. (2019). Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Annals of oncology, Vol.30 (8), pp. 1321-1328.

Coleman, N. Wotherspoon, A. Yousaf, N. Popat, S. (2019). Transformation to neuroendocrine carcinoma as a resistance mechanism to lorlatinib. Lung cancer, Vol.134, pp. 117-120.

Popat, S. (2019). Histologically Transformed SCLC From EGFR-Mutant NSCLC: Understanding the Wolf in Sheep’s Clothing. Journal of thoracic oncology, Vol.14 (10), pp. 1689-1691.

Popat, S. (2019). Hyperprogression with immunotherapy: Is it real?. Cancer, Vol.125 (8), pp. 1218-1220.

Tokaca, N. Barth, S. O’Brien, M. Bhosle, J. Fotiadis, N. Wotherspoon, A. Thompson, L. Popat, S. (2018). Molecular Adequacy of Image-Guided Rebiopsies for Molecular Retesting in Advanced Non–Small Cell Lung Cancer: A Single-Center Experience. Journal of thoracic oncology, Vol.13 (1), pp. 63-72.

Melosky, B. Popat, S. Gandara, D.R. (2018). An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach. Clinical lung cancer, Vol.19 (1), pp. 42-50.

Felip, E. Hirsh, V. Popat, S. Cobo, M. Fülöp, A. Dayen, C. Trigo, J.M. Gregg, R. Waller, C.F. Soria, J.-. Goss, G.D. Gordon, J. Wang, B. Palmer, M. Ehrnrooth, E. Gadgeel, S.M. (2018). Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy. Clinical lung cancer, Vol.19 (1), pp. 74-83.e11.

Lindsay, C.R. Shaw, E.C. Blackhall, F. Blyth, K.G. Brenton, J.D. Chaturvedi, A. Clarke, N. Dick, C. Evans, T.R. Hall, G. Hanby, A.M. Harrison, D.J. Johnston, S.R. Mason, M.D. Morton, D. Newton-Bishop, J. Nicholson, A.G. Oien, K.A. Popat, S. Rassl, D. Sharpe, R. Taniere, P. Walker, I. Wallace, W.A. West, N.P. Butler, R. Gonzalez de Castro, D. Griffiths, M. Johnson, P.W. (2018). Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. Esmo open, Vol.3 (6), pp. e000408-e000408. show abstract

Califano, R. Lal, R. Lewanski, C. Nicolson, M.C. Ottensmeier, C.H. Popat, S. Hodgson, M. Postmus, P.E. (2018). Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice. Future oncology, Vol.14 (23), pp. 2415-2431.

Planchard, D. Popat, S. Kerr, K. Novello, S. Smit, E.F. Faivre-Finn, C. Mok, T.S. Reck, M. Van Schil, P.E. Hellmann, M.D. Peters, S. (2018). Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology, Vol.29, pp. iv192-iv237.

Curioni, A. Felip, E. Dafni, U. Molina, M.-. Gautschi, O. Peters, S. Massutí, B. Palmero, R. Ponce, S. Carcereny, E. Früh, M. Pless, M. Popat, S. Cuffe, S. Karachaliou, N. Kammler, R. Kassapian, M. Roschitzki-Voser, H. Stahel, R.A. Rosell, R. (2018). Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial. Annals of oncology, Vol.29, pp. viii513-viii513.

Planchard, D. Popat, S. Kerr, K. Novello, S. Smit, E.F. Faivre-Finn, C. Mok, T.S. Reck, M. Van Schil, P.E. Hellmann, M.D. Peters, S. ESMO Guidelines Committee. Electronic address: [email protected], (2018). Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the european society for medical oncology, Vol.29 Suppl 4, pp. iv192-iv237.

Popat, S. (2018). Osimertinib as First-Line Treatment in EGFR-Mutated Non–Small-Cell Lung Cancer. New england journal of medicine, Vol.378 (2), pp. 192-193.

Camidge, D.R. Kim, H.R. Ahn, M.-. Yang, J.C. Han, J.-. Lee, J.-. Hochmair, M.J. Li, J.Y. Chang, G.-. Lee, K.H. Gridelli, C. Delmonte, A. Garcia Campelo, R. Kim, D.-. Bearz, A. Griesinger, F. Morabito, A. Felip, E. Califano, R. Ghosh, S. Spira, A. Gettinger, S.N. Tiseo, M. Gupta, N. Haney, J. Kerstein, D. Popat, S. (2018). Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer. New england journal of medicine, Vol.379 (21), pp. 2027-2039.

Juan, O. Yousaf, N. Popat, S. (2017). First-line Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors for EGFR Mutant Non-small Cell Lung Cancer: And the Winner is…. Clinical oncology, Vol.29 (1), pp. e1-e4.

Grosso, F. Steele, N. Novello, S. Nowak, A.K. Popat, S. Greillier, L. John, T. Leighl, N.B. Reck, M. Taylor, P. Planchard, D. Sørensen, J.B. Socinski, M.A. von Wangenheim, U. Loembé, A.B. Barrueco, J. Morsli, N. Scagliotti, G. (2017). Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. Journal of clinical oncology, Vol.35 (31), pp. 3591-3600. show abstract

Purpose LUME-Meso is a phase II/III randomized, double-blind trial designed to assess efficacy and safety of nintedanib plus chemotherapy as first-line treatment of malignant pleural mesothelioma (MPM). Phase II results are reported here. Patients and Methods Chemotherapy-naïve patients with unresectable, nonsarcomatoid MPM (Eastern Cooperative Oncology Group performance status 0 to 1), stratified by histology (epithelioid or biphasic), were randomly assigned in a 1:1 ratio to up to six cycles of pemetrexed and cisplatin plus nintedanib (200 mg twice daily) or placebo followed by nintedanib plus placebo monotherapy until progression. The primary end point was progression-free survival (PFS). Results Eighty-seven patients were randomly assigned. The median number of pemetrexed and cisplatin cycles was six; the median treatment duration for nintedanib was 7.8 months and 5.3 months for placebo. Primary PFS favored nintedanib (hazard ratio [HR], 0.56; 95% CI, 0.34 to 0.91; P = .017), which was confirmed in updated PFS analyses (HR, 0.54; 95% CI, 0.33 to 0.87; P = .010). A trend toward improved overall survival also favored nintedanib (HR, 0.77; 95% CI, 0.46 to 1.29; P = .319). Benefit was evident in epithelioid histology, with a median overall survival gain of 5.4 months (HR, 0.70; 95% CI, 0.40 to 1.21; P = .197; median [nintedanib v placebo], 20.6 months v 15.2 months) and median PFS gain of 4.0 months (HR, 0.49; 95% CI, 0.30 to 0.82; P = .006; median [nintedanib v placebo], 9.7 v 5.7 months). Neutropenia was the most frequent grade ≥ 3 adverse event (AE; nintedanib 43.2% v placebo 12.2%); rates of febrile neutropenia were low (4.5% in nintedanib group v 0% in placebo group). AEs leading to discontinuation were reported in 6.8% of those receiving nintedanib versus 17.1% of those in the placebo group. Conclusion Addition of nintedanib to pemetrexed plus cisplatin resulted in PFS improvement. AEs were manageable. The clinical benefit was evident in patients with epithelioid histology. The confirmatory phase III part of the study is ongoing. .

Yap, T.A. Macklin-Doherty, A. Popat, S. (2017). Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer. European journal of cancer, Vol.70, pp. 12-21.

Gautschi, O. Milia, J. Filleron, T. Wolf, J. Carbone, D.P. Owen, D. Camidge, R. Narayanan, V. Doebele, R.C. Besse, B. Remon-Masip, J. Janne, P.A. Awad, M.M. Peled, N. Byoung, C.-. Karp, D.D. Van Den Heuvel, M. Wakelee, H.A. Neal, J.W. Mok, T.S. Yang, J.C. Ou, S.-. Pall, G. Froesch, P. Zalcman, G. Gandara, D.R. Riess, J.W. Velcheti, V. Zeidler, K. Diebold, J. Früh, M. Michels, S. Monnet, I. Popat, S. Rosell, R. Karachaliou, N. Rothschild, S.I. Shih, J.-. Warth, A. Muley, T. Cabillic, F. Mazières, J. Drilon, A. (2017). Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. Journal of clinical oncology, Vol.35 (13), pp. 1403-1410. show abstract

Purpose In addition to prospective trials for non–small-cell lung cancers (NSCLCs) that are driven by less common genomic alterations, registries provide complementary information on patient response to targeted therapies. Here, we present the results of an international registry of patients with RET-rearranged NSCLCs, providing the largest data set, to our knowledge, on outcomes of RET-directed therapy thus far. Methods A global, multicenter network of thoracic oncologists identified patients with pathologically confirmed NSCLC that harbored a RET rearrangement. Molecular profiling was performed locally by reverse transcriptase polymerase chain reaction, fluorescence in situ hybridization, or next-generation sequencing. Anonymized data—clinical, pathologic, and molecular features—were collected centrally and analyzed by an independent statistician. Best response to RET tyrosine kinase inhibition administered outside of a clinical trial was determined by RECIST v1.1. Results By April 2016, 165 patients with RET-rearranged NSCLC from 29 centers across Europe, Asia, and the United States were accrued. Median age was 61 years (range, 29 to 89 years). The majority of patients were never smokers (63%) with lung adenocarcinomas (98%) and advanced disease (91%). The most frequent rearrangement was KIF5B-RET (72%). Of those patients, 53 received one or more RET tyrosine kinase inhibitors in sequence: cabozantinib (21 patients), vandetanib (11 patients), sunitinib (10 patients), sorafenib (two patients), alectinib (two patients), lenvatinib (two patients), nintedanib (two patients), ponatinib (two patients), and regorafenib (one patient). The rate of any complete or partial response to cabozantinib, vandetanib, and sunitinib was 37%, 18%, and 22%, respectively. Further responses were observed with lenvantinib and nintedanib. Median progression-free survival was 2.3 months (95% CI, 1.6 to 5.0 months), and median overall survival was 6.8 months (95% CI, 3.9 to 14.3 months). Conclusion Available multikinase inhibitors had limited activity in patients with RET-rearranged NSCLC in this retrospective study. Further investigation of the biology of RET-rearranged lung cancers and identification of new targeted therapeutics will be required to improve outcomes for these patients. .

Yap, T.A. Popat, S. (2017). Targeting MET Exon 14 Skipping Alterations: Has Lung Cancer MET Its Match?. Journal of thoracic oncology, Vol.12 (1), pp. 12-14.

Juan, O. Popat, S. (2017). Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients. Lung cancer, Vol.104, pp. 131-133.

Juan, O. Popat, S. (2017). Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications. Therapeutic advances in medical oncology, Vol.9 (3), pp. 201-216.

Papadatos-Pastos, D. Roda, D. De Miguel Luken, M.J. Petruckevitch, A. Jalil, A. Capelan, M. Michalarea, V. Lima, J. Diamantis, N. Bhosle, J. Molife, L.R. Banerji, U. de Bono, J.S. Popat, S. O'Brien, M.E. Yap, T.A. (2017). Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit. European journal of cancer, Vol.75, pp. 56-62.

Dolly, S.O. Collins, D.C. Sundar, R. Popat, S. Yap, T.A. (2017). Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. Drugs, Vol.77 (8), pp. 813-827.

Rosell, R. Dafni, U. Felip, E. Curioni-Fontecedro, A. Gautschi, O. Peters, S. Massutí, B. Palmero, R. Aix, S.P. Carcereny, E. Früh, M. Pless, M. Popat, S. Kotsakis, A. Cuffe, S. Bidoli, P. Favaretto, A. Froesch, P. Reguart, N. Puente, J. Coate, L. Barlesi, F. Rauch, D. Thomas, M. Camps, C. Gómez-Codina, J. Majem, M. Porta, R. Shah, R. Hanrahan, E. Kammler, R. Ruepp, B. Rabaglio, M. Kassapian, M. Karachaliou, N. Tam, R. Shames, D.S. Molina-Vila, M.A. Stahel, R.A. (2017). Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. The lancet respiratory medicine, Vol.5 (5), pp. 435-444.

Popat, S. Mellemgaard, A. Reck, M. Hastedt, C. Griebsch, I. (2017). Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options. Future oncology, Vol.13 (13), pp. 1159-1171.

Nimako, K. Ayite, B. Priest, K. Severn, J. Fries, H.M. Gunapala, R. Bhosle, J. Popat, S. O'Brien, M. (2017). A randomised assessment of the use of a quality of life questionnaire with or without intervention in patients attending a thoracic cancer clinic. European journal of cancer care, Vol.26 (4), pp. e12402-e12402.

Yap, T.A. Aerts, J.G. Popat, S. Fennell, D.A. (2017). Novel insights into mesothelioma biology and implications for therapy. Nature reviews cancer, Vol.17 (8), pp. 475-488.

Capelan, M. Roda, D. Geuna, E. Rihawi, K. Bodla, S. Kaye, S.B. Bhosle, J. Banerji, U. O’Brien, M. de Bono, J.S. Popat, S. Yap, T.A. (2017). Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?. Lung cancer, Vol.111, pp. 6-11.

Yousaf, N. Popat, S. (2017). Endocrine manifestations of malignancy. Medicine, Vol.45 (9), pp. 547-550.

Tokaca, N. Wotherspoon, A. Nicholson, A.G. Fotiadis, N. Thompson, L. Popat, S. (2017). Lack of response to nivolumab in a patient with EGFR -mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer. Lung cancer, Vol.111, pp. 65-68.

Califano, R. Greystoke, A. Lal, R. Thompson, J. Popat, S. (2017). Management of ceritinib therapy and adverse events in patients with ALK -rearranged non-small cell lung cancer. Lung cancer, Vol.111, pp. 51-58.

Scagliotti, G.V. Gaafar, R. Nowak, A.K. Reck, M. Tsao, A.S. van Meerbeeck, J. Vogelzang, N.J. Nakano, T. von Wangenheim, U. Velema, D. Morsli, N. Popat, S. (2017). LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma. Clinical lung cancer, Vol.18 (5), pp. 589-593.

Yang, J.C. Ou, S.-. De Petris, L. Gadgeel, S. Gandhi, L. Kim, D.-. Barlesi, F. Govindan, R. Dingemans, A.-. Crino, L. Lena, H. Popat, S. Ahn, J.S. Dansin, E. Golding, S. Bordogna, W. Balas, B. Morcos, P.N. Zeaiter, A. Shaw, A.T. (2017). Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK -positive Non-Small Cell Lung Cancer. Journal of thoracic oncology, Vol.12 (10), pp. 1552-1560.

Popat, S. (2017). Do Statins Improve Survival in Small-Cell Lung Cancer?. Journal of clinical oncology, Vol.35 (14), pp. 1497-1498.

Juan, O. Popat, S. (2017). Ablative Therapy for Oligometastatic Non–Small Cell Lung Cancer. Clinical lung cancer, Vol.18 (6), pp. 595-606.

Crabb, S.J. Martin, K. Abab, J. Ratcliffe, I. Thornton, R. Lineton, B. Ellis, M. Moody, R. Stanton, L. Galanopoulou, A. Maishman, T. Geldart, T. Bayne, M. Davies, J. Lamb, C. Popat, S. Joffe, J.K. Nutting, C. Chester, J. Hartley, A. Thomas, G. Ottensmeier, C. Huddart, R. King, E. (2017). COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss. European journal of cancer, Vol.87, pp. 75-83.

Pender, A. Rana, S. Delgado, E.I. Proszek, P. Garcia-Murillas, I. Bhosle, J. O'Brien, M. Palma, J.F. Turner, N.C. Popat, S. Downward, J. Gonzalez, D. (2016). 3 EGFR mutant circulating tumour DNA detection in advanced lung adenocarcinoma: optimising the application of a ctDNA diagnostic to real world clinical practice. Lung cancer, Vol.91, pp. S2-S2.

Pearson, A. Smyth, E. Babina, I.S. Herrera-Abreu, M.T. Tarazona, N. Peckitt, C. Kilgour, E. Smith, N.R. Geh, C. Rooney, C. Cutts, R. Campbell, J. Ning, J. Fenwick, K. Swain, A. Brown, G. Chua, S. Thomas, A. Johnston, S.R. Ajaz, M. Sumpter, K. Gillbanks, A. Watkins, D. Chau, I. Popat, S. Cunningham, D. Turner, N.C. (2016). High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. Cancer discovery, Vol.6 (8), pp. 838-851.

Marquez-Medina, D. Martin-Marco, A. Popat, S. (2016). Watch the weathercock: changes in re-staging 18F-FDG PET/CT scan predict the probability of relapse in locally advanced non-small cell lung cancer. Clinical and translational oncology, Vol.18 (2), pp. 228-232.

Abdelraouf, F. Smit, E. Hasan, B. Menis, J. Popat, S. van Meerbeeck, J.P. Surmont, V.F. Baas, P. O'Brien, M. (2016). Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a ‘chemosensitive’ relapse: A single-arm phase II study (EORTC-08061). European journal of cancer, Vol.54, pp. 35-39.

Kumar, R. Lu, S.K. Minchom, A. Sharp, A. Davidson, M. Gunapala, R. Yap, T.A. Bhosle, J. Popat, S. O’Brien, M.E. (2016). A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients. Cancer chemotherapy and pharmacology, Vol.77 (2), pp. 375-383.

Malottki, K. Popat, S. Deeks, J.J. Riley, R.D. Nicholson, A.G. Billingham, L. (2016). Problems of variable biomarker evaluation in stratified medicine research—A case study of ERCC1 in non-small-cell lung cancer. Lung cancer, Vol.92, pp. 1-7.

Marquez-Medina, D. Popat, S. (2016). Eventual role of EGFR-tyrosine kinase inhibitors in early-stage non-small-cell lung cancer. Future oncology, Vol.12 (6), pp. 815-825.

Schuler, M. Wu, Y.-. Hirsh, V. O’Byrne, K. Yamamoto, N. Mok, T. Popat, S. Sequist, L.V. Massey, D. Zazulina, V. Yang, J.C. (2016). First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. Journal of thoracic oncology, Vol.11 (3), pp. 380-390.

Schuler, M. Yang, J.C. Park, K. Kim, J.-. Bennouna, J. Chen, Y.-. Chouaid, C. De Marinis, F. Feng, J.-. Grossi, F. Kim, D.-. Liu, X. Lu, S. Strausz, J. Vinnyk, Y. Wiewrodt, R. Zhou, C. Wang, B. Chand, V.K. Planchard, D. Ignatius Ou, S. Planchard, D. Park, K. Schuler, M. Yang, J. Chand, V. Rohr, K. Bagnes, C. Martin, C.M. Recondo, G. Zarba, J.J. Blajman, C. Richardet, M. McLachlan, S.-. Parente, P. Underhill, C. Crombie, C. Mainwaring, P. Greil, R. Humblet, Y. Bustin, F. Carestia, L. Galdermans, D. Lambrechts, M. Delval, L. Vercauter, P. Zhou, C. Wang, J. Huang, C. Lin, X. Wu, Y. Liu, X. Cheng, Y. Qin, S. Feng, J. Huang, J. Zhang, Y. Lu, S. Zereu, M. Garicochea, B. Zadra, C.A. Riska, H. Alanko, T. Cadranel, J. Chouaid, C. Zalcman, G. Sibilot, D.M. Perol, M. Planchard, D. Bennouna, J. Fournel, P. Gervais, R. Rotarski, M. Coudert, B. Schuler, M. Thomas, M. Wehler, T. Faehling, M. Keilholz, U. Laack, E. von Pawel, J. Huber, R. Dickgreber, N. Wiewrodt, R. Mark, Z. Tehenes, S. Strausz, J. Sarosi, V. Prabhash, K. Jain, M. Venkatesan, S. Sharma, L. Dadhich, H. Nagarkar, R.V. Onn, A. Gottfried, M. Stemmer, S. Migliorino, M.R. Grossi, F. Bidoli, P. Bearz, A. Gridelli, C. Milandri, C. Platania, M. Ceresoli, G.L. Cruciani, G. Delgado, F.G. Gonzalez Perez, J.L. Luna, G.A. Baca, O.P. Aerts, J.G. Stigt, J.A. Dingemans, A.M. Herder, G.J. Gans, S.J. Salas Sánchez, J.F. Alvarez Barreda, R.L. Pantigoso, W.R. Palomino, O.L. Jaskiewicz, P. Kazarnowicz, A. Serwatowski, P. Szczesna, A. Jassem, J. Lubennikov, V. Karaseva, N. Orlov, S. Ragulin, Y. Garrido, P. González Larriba, J.L. Camps, C. Campelo, R.G. Lianes, P. Cobo, M. Felip, E. Kim, D.-. Kim, S.-. Park, K. Kim, J.-. Han, J.-. Kim, Y.-. Yang, C.-. Hsia, T.-. Chen, Y.-. Tsai, Y.-. Chang, G.-. Tsao, T.C. Su, W.-. Huang, M.-. Ho, C.-. Hsieh, R.-. Vinnyk, Y. Popovych, O. Ponomarova, O. Bondarenko, I. Polishchuk, I. Shah, R. Mitra, S. Popat, S. Spicer, J. Toy, E. Popat, S. Talbot, T. Brown, E. Upadhyay, S. Summers, Y. Gurtler, J. Meza, L. Thropay, J. (2016). Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Annals of oncology, Vol.27 (3), pp. 417-423.

Anandappa, G. Popat, S. (2016). Management of lung cancer. Medicine, Vol.44 (4), pp. 244-248.

Weller, A. O'Brien, M.E. Ahmed, M. Popat, S. Bhosle, J. McDonald, F. Yap, T.A. Du, Y. Vlahos, I. deSouza, N.M. (2016). Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer. European journal of cancer, Vol.59, pp. 65-78.

Sharp, A. Bhosle, J. Abdelraouf, F. Popat, S. O'Brien, M. Yap, T.A. (2016). Development of molecularly targeted agents and immunotherapies in small cell lung cancer. European journal of cancer, Vol.60, pp. 26-39.

Minchom, A. Punwani, R. Filshie, J. Bhosle, J. Nimako, K. Myerson, J. Gunapala, R. Popat, S. O'Brien, M.E. (2016). A randomised study comparing the effectiveness of acupuncture or morphine versus the combination for the relief of dyspnoea in patients with advanced non-small cell lung cancer and mesothelioma. European journal of cancer, Vol.61, pp. 102-110.

Viola, P. Maurya, M. Croud, J. Gazdova, J. Suleman, N. Lim, E. Newsom-Davis, T. Plowman, N. Rice, A. Montero, M.A. Gonzalez de Castro, D. Popat, S. Nicholson, A.G. (2016). A Validation Study for the Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer. Journal of thoracic oncology, Vol.11 (7), pp. 1029-1039.

Marquez-Medina, D. Popat, S. (2016). Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases. Clinical and translational oncology, Vol.18 (8), pp. 760-768.

Novello, S. Barlesi, F. Califano, R. Cufer, T. Ekman, S. Levra, M.G. Kerr, K. Popat, S. Reck, M. Senan, S. Simo, G.V. Vansteenkiste, J. Peters, S. (2016). Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology, Vol.27, pp. v1-v27.

Khalifa, J. Amini, A. Popat, S. Gaspar, L.E. Faivre-Finn, C. (2016). Brain Metastases from NSCLC: Radiation Therapy in the Era of Targeted Therapies. Journal of thoracic oncology, Vol.11 (10), pp. 1627-1643.

Puglisi, M. Stewart, A. Thavasu, P. Frow, M. Carreira, S. Minchom, A. Punwani, R. Bhosle, J. Popat, S. Ratoff, J. de Bono, J. Yap, T.A. O''Brien, M. Banerji, U. (2016). Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions. Oncology, Vol.90 (5), pp. 280-288.

Aitken, K. Popat, S. Nutting, C. McDonald, F. (2015). 76: Patterns of extra-cranial disease progression in epidermal growth factor receptor (EGFR) mutant metastatic non-small cell lung cancer (NSCLC) patients on a tyrosine kinase inhibitor (TKI). Lung cancer, Vol.87, pp. S30-S30.

Yang, J.C. Wu, Y.-. Schuler, M. Sebastian, M. Popat, S. Yamamoto, N. Zhou, C. Hu, C.-. O'Byrne, K. Feng, J. Lu, S. Huang, Y. Geater, S.L. Lee, K.Y. Tsai, C.-. Gorbunova, V. Hirsh, V. Bennouna, J. Orlov, S. Mok, T. Boyer, M. Su, W.-. Lee, K.H. Kato, T. Massey, D. Shahidi, M. Zazulina, V. Sequist, L.V. (2015). Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. The lancet oncology, Vol.16 (2), pp. 141-151.

Popat, S. Mellemgaard, A. Fahrbach, K. Martin, A. Rizzo, M. Kaiser, R. Griebsch, I. Reck, M. (2015). Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis. Future oncology, Vol.11 (3), pp. 409-420.

Scagliotti, G.V. Bondarenko, I. Blackhall, F. Barlesi, F. Hsia, T.-. Jassem, J. Milanowski, J. Popat, S. Sanchez-Torres, J.M. Novello, S. Benner, R.J. Green, S. Molpus, K. Soria, J.-. Shepherd, F.A. (2015). Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer. Annals of oncology, Vol.26 (3), pp. 497-504.

Lim, E. Nicholson, A.G. Padley, S. Popat, S. (2015). Never smoker with ground glass opacities on CT. The lancet respiratory medicine, Vol.3 (4), pp. 328-328.

Pender, A. Popat, S. (2015). The efficacy of crizotinib in patients with ALK-positive nonsmall cell lung cancer. Therapeutic advances in respiratory disease, Vol.9 (3), pp. 97-104.

O’Brien, M.E. Gaafar, R. Hasan, B. Menis, J. Cufer, T. Popat, S. Woll, P.J. Surmont, V. Georgoulias, V. Montes, A. Blackhall, F. Hennig, I. Schmid-Bindert, G. Baas, P. (2015). Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064). European journal of cancer, Vol.51 (12), pp. 1511-1528.

Hall, P.E. Spicer, J. Popat, S. (2015). Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung. Future oncology, Vol.11 (15), pp. 2175-2191.

Soria, J.-. Felip, E. Cobo, M. Lu, S. Syrigos, K. Lee, K.H. Göker, E. Georgoulias, V. Li, W. Isla, D. Guclu, S.Z. Morabito, A. Min, Y.J. Ardizzoni, A. Gadgeel, S.M. Wang, B. Chand, V.K. Goss, G.D. (2015). Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. The lancet oncology, Vol.16 (8), pp. 897-907.

Stephens, R.J. Whiting, C. Cowan, K. (2015). Research priorities in mesothelioma: A James Lind Alliance Priority Setting Partnership. Lung cancer, Vol.89 (2), pp. 175-180.

Marquez-Medina, D. Popat, S. (2015). Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer. Future oncology, Vol.11 (18), pp. 2525-2540.

Middleton, G. Popat, S. Walker, I. Mulatero, C. Spicer, J. Summers, Y. Yap, T.A. Crack, L.R. Billingham, L.J. (2015). The National Lung Matrix Trial: Multi-Drug, Genetic Marker-Directed, Multi-Arm Phase II Trial in Non-Small Cell Lung Cancer. Journal of thoracic oncology, Vol.10 (9), pp. S763-S764.

Gennatas, S. Anbunathan, H. Montero, A. Nicholson, A.G. Popat, S. Bowcock, A.M. (2015). Validation of a Specific Missense GTF2I Mutation in More Indolent Thymic Epithelial Tumours. Journal of thoracic oncology, Vol.10 (9), pp. S403-S403.

Billingham, L.J. Brock, K. Crack, L.R. Popat, S. Middleton, G. (2015). Using a Bayesian Adaptive Phase II Trial Design to Test Multiple Genetic-Marker-Directed Drugs in the National Lung Matrix Trial. Journal of thoracic oncology, Vol.10 (9), pp. S372-S372.

Marquez-Medina, D. Popat, S. (2015). Systemic therapy for pulmonary carcinoids. Lung cancer, Vol.90 (2), pp. 139-147.

Cheng, L. Tunariu, N. Collins, D.J. Blackledge, M.D. Riddell, A.M. Leach, M.O. Popat, S. Koh, D.-. (2015). Response evaluation in mesothelioma: Beyond RECIST. Lung cancer, Vol.90 (3), pp. 433-441.

Balachandran, K. Okines, A. Gunapala, R. Morganstein, D. Popat, S. (2015). Resolution of severe hyponatraemia is associated with improved survival in patients with cancer. Bmc cancer, Vol.15 (1).

Abdelraouf, F. Sharp, A. Maurya, M. Mair, D. Wotherspoon, A. Leary, A. Gonzalez de Castro, D. Bhosle, J. Nassef, A. Gaafar, T. Popat, S. Yap, T.A. O’Brien, M. (2015). Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice. Bmc research notes, Vol.8 (1).

Middleton, G. Crack, L.R. Popat, S. Swanton, C. Hollingsworth, S.J. Buller, R. Walker, I. Carr, T.H. Wherton, D. Billingham, L.J. (2015). The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer. Annals of oncology, Vol.26 (12), pp. 2464-2469.

Gennatas, S. Noble, J. Stanway, S. Gunapala, R. Chowdhury, R. Wotherspoon, A. Benepal, T. Popat, S. (2015). Patterns of relapse in extrapulmonary small cell carcinoma: retrospective analysis of outcomes from two cancer centres. Bmj open, Vol.5 (1), pp. e006440-e006440.

Marquez-Medina, D. Popat, S. (2015). Steroid-related emphysematous cystitis in an EGFR-mutant patient with lung adenocarcinoma while on gefitinib treatment. Cancer treatment communications, Vol.4, pp. 86-88.

Pender, A. Coward, J. Gunapala, R. Bhosle, J. O'Brien, M. Popat, S. (2014). 38 Patterns of relapse and detection method in patients with resected non-small cell lung cancer (NSCLC) – a single institution experience. Lung cancer, Vol.83, pp. S15-S15.

Freidin, M.B. Mair, D. Tay, A. Freydina, D.V. Chudasama, D. Popat, S. Nicholson, A.G. Rice, A. Montero-Fernandez, A. Anikin, V. de Castro, D.G. Lim, E. (2014). 8 The utility of peripheral blood circulating tumour cells for the detection of KRAS, EGFR and BRAF mutations in primary lung cancer. Lung cancer, Vol.83, pp. S3-S4.

Twelves, C. Chmielowska, E. Havel, L. Popat, S. Swieboda-Sadlej, A. Sawrycki, P. Bycott, P. Ingrosso, A. Kim, S. Williams, J.A. Chen, C. Olszanski, A.J. de Besi, P. Schiller, J.H. (2014). Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer. Annals of oncology, Vol.25 (1), pp. 132-138.

Popat, S. (2014). Patient reported outcomes from LUX-Lung 3: first-line afatinib is superior to chemotherapy-would patients agree?. Annals of palliative medicine, Vol.3 (1), pp. 19-21. show abstract

Abdelraouf, F. de Castro, D.G. Wotherspoon, A. Maurya, M. Mair, D. Bhosle, J. Popat, S. O'Brien, M. (2014). INVESTIGATING MOLECULAR BIOMARKERS IN SCLC. Journal of thoracic oncology, Vol.9 (4), pp. S30-S30.

McDonald, F. Popat, S. (2014). Combining targeted agents and hypo- and hyper-fractionated radiotherapy in NSCLC. Journal of thoracic disease, Vol.6 (4), pp. 356-368.

Le Quesne, J. Maurya, M. Yancheva, S.G. O’Brien, M. Popat, S. Wotherspoon, A.C. de Castro, D.G. Nicholson, A.G. (2014). A Comparison of Immunohistochemical Assays and FISH in Detecting the ALK Translocation in Diagnostic Histological and Cytological Lung Tumor Material. Journal of thoracic oncology, Vol.9 (6), pp. 769-774.

Patton, S. Normanno, N. Blackhall, F. Murray, S. Kerr, K.M. Dietel, M. Filipits, M. Benlloch, S. Popat, S. Stahel, R. Thunnissen, E. (2014). Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing. British journal of cancer, Vol.111 (2), pp. 413-420.

Khan, F. Ottensmeier, C. Popat, S. Dua, D. Dorey, N. Ellis, S. Szabo, M. Upadhyay, S. Califano, R. Chan, S. Lee, L. Ali, C.W. Nicolson, M. Bates, A.T. Button, M. Chaudhuri, A. Mulvenna, P. Shaw, H.M. Danson, S.J. (2014). Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme. European journal of cancer, Vol.50 (10), pp. 1717-1721.

Pender, A. Popat, S. (2014). Understanding lung cancer molecular subtypes. Clinical practice, Vol.11 (4), pp. 441-453.

Puglisi, M. Thavasu, P. Stewart, A. de Bono, J.S. O’Brien, M.E. Popat, S. Bhosle, J. Banerji, U. (2014). AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines. Lung cancer, Vol.85 (2), pp. 141-146.

Popat, S. Mok, T. Yang, J.C. Wu, Y.-. Lungershausen, J. Stammberger, U. Griebsch, I. Fonseca, T. Paz-Ares, L. (2014). Afatinib in the treatment of EGFR mutation-positive NSCLC – A network meta-analysis. Lung cancer, Vol.85 (2), pp. 230-238.

Gann, C.-. Reck, M. Leighl, N. Nowak, A. Pavlakis, N. Popat, S. Sorensen, J.B. Mueller, M. Von Wangenheim, U. Scagliotti, G. (2014). NINTEDANIB PLUS PEMETREXED/CISPLATIN FOLLOWED BY MAINTENANCE NINTEDANIB FOR UNRESECTABLE MALIGNANT PLEURAL MESOTHELIOMA-AN INTERNATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY. Journal of thoracic oncology, Vol.9 (9), pp. S172-S172.

Reck, M. Popat, S. Reinmuth, N. De Ruysscher, D. Kerr, K.M. Peters, S. (2014). Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology, Vol.25, pp. iii27-iii39.

O'Brien, M.E. Gaafar, R. Hasan, B. Menis, J. Cufer, T. Popat, S. Woll, P. Surmont, V. Georgoulias, V. Montes, A. Blackhall, F. Hennig, I. Schmid-Bindert, G. Baas, P. (2014). Double Blind Randomized Phase III Study of Maintenance Pazopanib® (Pz) Versus Placebo (P) in Non Small Cell Lung Cancer (Nsclc) Patients (Pts) Non Progressive After First Line Chemotherapy [Ct] (Eortc Lung Cancer Group, 08092): Mapping. Annals of oncology, Vol.25, pp. iv435-iv435.

Freydin, M. Freydina, D.V. Chudasama, D. Leung, M. Popat, S. Gonzalez-De-Castro, D. Rice, A. Fernandez, A.M. Nicholson, A.G. Lim, E. (2014). A Blood Based Egfr Mutation Analysis in Circulating Plasma Dna for Prediction of Primary Tumour Mutations in Lung Cancer. Annals of oncology, Vol.25, pp. iv68-iv68.

Rossi, A. Chiodini, P. Sun, J.-. O'Brien, M.E. von Plessen, C. Barata, F. Park, K. Popat, S. Bergman, B. Parente, B. Gallo, C. Gridelli, C. Perrone, F. Di Maio, M. (2014). Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. The lancet oncology, Vol.15 (11), pp. 1254-1262.

Popat, S. Lungershausen, J. Griebsch, I. Marten, A. Wu, Y.L. (2014). Treatments for EGFR Mutation-Positive (M+) NSCLC Patients – A Network Meta-Analysis (NMA) by Mutation Type. Value in health, Vol.17 (7), pp. A615-A615.

Linch, M. Gennatas, S. Kazikin, S. Iqbal, J. Gunapala, R. Priest, K. Severn, J. Norton, A. Ayite, B. Bhosle, J. O’Brien, M. Popat, S. (2014). A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice. Bmc cancer, Vol.14 (1).

Minchom, A.R. Saksornchai, K. Bhosle, J. Gunapala, R. Puglisi, M. Lu, S.K. Nimako, K. Coward, J. Yu, K.C. Bordi, P. Popat, S. O'Brien, M.E. (2014). An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of severe neutropenic toxicity. Bmj open respiratory research, Vol.1 (1), pp. e000061-e000061.

NIMAKO, K. GUNAPALA, R. POPAT, S. O'BRIEN, M.E. (2013). Patient factors, health care factors and survival from lung cancer according to ethnic group in the south of London, UK. European journal of cancer care, Vol.22 (1), pp. 79-87.

Pender, A. Coward, J. Gunapala, R. Bhosle, J. O'Brien, M. Popat, S. (2013). 33 Outcomes of patients undergoing adjuvant platinum–vinorelbine chemotherapy for resected non-small cell lung cancer (NSCLC). Lung cancer, Vol.79, pp. S12-S12.

Freidin, M.B. Tay, A. Chudasama, D. Nicholson, A.G. Rice, A. Bamsey, O. Higgins, A. Popat, S. Anikin, V. Lim, E. (2013). 15 Non-invasive KRAS and EGFR mutation testing of primary lung cancer via peripheral blood circulating tumour cells. Lung cancer, Vol.79, pp. S5-S6.

Khan, F. Ottensmeier, C. Popat, S. Danson, S.J. (2013). 30 Afatanib use in non-small cell cancer patients whose tumours have been previously sensitive to EGFR inhibitors: the UK Named Patient Use experience. Lung cancer, Vol.79, pp. S10-S11.

Weickhardt, A.J. Doebele, R.C. Purcell, W.T. Bunn, P.A. Oton, A.B. Rothman, M.S. Wierman, M.E. Mok, T. Popat, S. Bauman, J. Nieva, J. Novello, S. Ou, S.-. Camidge, D.R. (2013). Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. Cancer, Vol.119 (13), pp. 2383-2390.

Popat, S. Wotherspoon, A. Nutting, C.M. Gonzalez, D. Nicholson, A.G. O’Brien, M. (2013). Transformation to “high grade” neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma. Lung cancer, Vol.80 (1), pp. 1-4.

Nimako, K. Lu, S.-. Ayite, B. Priest, K. Winkley, A. Gunapala, R. Popat, S. O'Brien, M.E. (2013). A Pilot Study of a Novel Home Telemonitoring System for Oncology Patients Receiving Chemotherapy. Journal of telemedicine and telecare, Vol.19 (3), pp. 148-152.

Alrifai, D. Popat, S. Ahmed, M. Gonzalez, D. Nicholson, A.G. Parcq, J.D. Benepal, T. (2013). A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations. Lung cancer, Vol.80 (3), pp. 339-340.

Lim, E. Popat, S. (2013). What exactly are we doing to improve low lung cancer survival in the United Kingdom?. Thorax, Vol.68 (6), pp. 504-505.

Papa, S. Popat, S. Shah, R. Prevost, A.T. Lal, R. McLennan, B. Cane, P. Lang-Lazdunski, L. Viney, Z. Dunn, J.T. Barrington, S. Landau, D. Spicer, J. (2013). Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy. Journal of thoracic oncology, Vol.8 (6), pp. 783-787.

O’Brien, M.E. Gaafar, R.M. Popat, S. Grossi, F. Price, A. Talbot, D.C. Cufer, T. Ottensmeier, C. Danson, S. Pallis, A. Hasan, B. Van Meerbeeck, J.P. Baas, P. (2013). Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). European journal of cancer, Vol.49 (13), pp. 2815-2822.

Früh, M. De Ruysscher, D. Popat, S. Crinò, L. Peters, S. Felip, E. (2013). Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology, Vol.24, pp. vi99-vi105.

Balachandran, K. Popat, S. (2013). Endocrine manifestations of malignancy. Medicine, Vol.41 (10), pp. 570-572.

Le Quesne, J. Maurya, M. De Castro, D.G. Popat, S. Wotherspoon, A. Nicholson, A. (2013). A COMPARISON OF FISH AND IMMUNOHISTOCHEMISTRY IN THE DETECTION OF ALK REARRANGEMENT IN LUNG ADENOCARCINOMA. Journal of thoracic oncology, Vol.8, pp. S1085-S1086.

de Mello, R.A. Madureira, P. Carvalho, L.S. Araújo, A. O’Brien, M. Popat, S. (2013). EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer. Pharmacogenomics, Vol.14 (14), pp. 1765-1777.

Lim, E. De Castro, D.G. Popat, S. Shaw, E. Walker, I. Johnson, P. Bamsey, O. Higgins, A. Osadolor, T. Renouf, L. Nicholson, A.G. (2013). FREQUENCY IN EGFR, K-RAS, BRAF AND ALK MUTATIONS IN A COHORT OF CANCERS: ALK TRANSLOCATIONS ARE MORE FREQUENTLY SEEN IN ADVANCED DISEASE. Journal of thoracic oncology, Vol.8, pp. S1222-S1223.

Yap, T.A. Popat, S. (2013). The role of afatinib in the management of non-small cell lung carcinoma. Expert opinion on drug metabolism & toxicology, Vol.9 (11), pp. 1529-1539.

Pender, A. Coward, J. Gunapala, R. Brien, M.O. Bhosle, J. Popat, S. (2013). OUTCOMES OF PATIENTS UNDERGOING ADJUVANT PLATINUM- VINORELBINE CHEMOTHERAPY FOR RESECTED NON- SMALL CELL LUNG CANCER (NSCLC). Journal of thoracic oncology, Vol.8, pp. S1168-S1168.

Freydina, D.V. Tay, A. Chudasama, D. Freidin, M.B. Nicholson, A.G. Rice, A. Montero-Fernandez, A. Popat, S. Anikin, V. Lim, E. (2013). DIAGNOSTIC PERFORMANCE OF A FILTER-BASED ANTIBODY-INDEPENDENT PERIPHERAL BLOOD CIRCULATING TUMOUR CELL CAPTURE PAIRED WITH CYTOMORPHOLOGIC CRITERIA FOR THE DIAGNOSIS OF LUNG CANCER. Journal of thoracic oncology, Vol.8, pp. S1278-S1278.

Gennatas, S. Stanway, S.J. Thomas, R. Min, T. Shah, R. O’Brien, M.E. Popat, S. (2013). Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma. Bmc cancer, Vol.13 (1).

Myerson, J. O'Brien, M. Waddell, T. Reid, A. Gunapala, R. Starling, N. Seet, J.E. Nimako, K. Popat, S. (2012). 76 The UK ‘two week rule’ for lung cancer – 5-year survival update. Lung cancer, Vol.75, pp. S25-S26.

Pender, A. Letsa, I. Reid, A. Waddell, T. Nimako, K. Tan, D. Xynos, I. Ayite, B. Priest, K. Watson, S. Stewart, Z. Severn, J. Popat, S. O'Brien, M. (2012). 21 Weekly paclitaxel and three weekly docetaxel appear active and well-tolerated in third and fourth-line advanced NSCLC patients. Lung cancer, Vol.75, pp. S7-S7.

O’Brien, M.E. Myerson, J.S. Coward, J.I. Puglisi, M. Trani, L. Wotherspoon, A. Sharma, B. Cook, G. Ashley, S. Gunapala, R. Chua, S. Popat, S. (2012). A phase II study of 18F-fluorodeoxyglucose PET–CT in non-small cell lung cancer patients receiving erlotinib (Tarceva®); objective and symptomatic responses at 6 and 12weeks. European journal of cancer, Vol.48 (1), pp. 68-74.

Leary, A.F. Castro, D.G. Nicholson, A.G. Ashley, S. Wotherspoon, A. O’Brien, M.E. Popat, S. (2012). Establishing an EGFR mutation screening service for non-small cell lung cancer – Sample quality criteria and candidate histological predictors. European journal of cancer, Vol.48 (1), pp. 61-67.

Coward, J.I. Nathavitharana, R. Popat, S. (2012). True hypoglycaemia secondary to treatment with granulocyte colony stimulating factor (G-CSF) in a diabetic patient with non-small cell lung cancer. Lung cancer, Vol.75 (1), pp. 133-135.

Freidin, M. Nicholson, A. Popat, S. Moffatt, M. Cookson, W. Lim, E. (2012). 6 Distribution profile of baseline gene expression to standardise tumour expression: a pilot study of cisplatin resistant genes in lung cancer. Lung cancer, Vol.75, pp. S2-S3.

Tai, F.W. Khor, K.S. Popat, S. Beckles, M. Leung, M. Lim, E. (2012). 36 Oncologists', physicians' and surgeons' opinions on the perceived value and appropriateness of the speciality to inform patients on adjuvant chemotherapy after radical surgery for non-small cell lung cancer. Lung cancer, Vol.75, pp. S12-S12.

Popat, S. Gonzalez, D. Min, T. Swansbury, J. Dainton, M. Croud, J.G. Rice, A.J. Nicholson, A.G. (2012). ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma. Lung cancer, Vol.75 (3), pp. 300-305.

Nimako, K. Popat, S. (2012). Management of lung cancer. Medicine, Vol.40 (4), pp. 202-207.

Coward, J.I. Ding, N.-. Feakins, R. Kocher, H. Popat, S. Szlosarek, P.W. (2012). Chemotherapy-induced bowel obstruction in small cell lung cancer: a case report. Medical oncology, Vol.29 (4), pp. 2623-2625.

O'Connor, S.J. Elliott, S. Chinegwundoh, J. Popat, S. Rhode, A.L. (2011). 67 Retrospective audit of a district general hospital (DGH) lung multi-disciplinary team (MDT) - lessons from misses and near-misses of treatment deadline. Lung cancer, Vol.71, pp. S23-S23.

Okera, M. Chan, S. Dernede, U. Larkin, J. Popat, S. Gilbert, D. Jones, L. Osuji, N. Sykes, H. Oakley, C. Pickering, L. Lofts, F. Chowdhury, S. (2011). A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network Interpretation of study results in light of NCAG/NCEPOD findings. British journal of cancer, Vol.104 (3), pp. 407-412.

Myerson, J.S. Nimako, K. Ranu, H. Madden, B. Popat, S. O'Brien, M. (2011). RANDOMISED EVALUATION OF STENTS TO OPEN RESTRICTED AIRWAYS IN PATIENTS WITH CENTRALLY PLACED NON-SMALL CELL LUNG CANCER (RESTORE - AIR). Journal of thoracic oncology, Vol.6 (6), pp. S1201-S1202.

Reid, A. Waddell, T.S. Nimako, K. Tan, D. Xynos, I. Popat, S. O'Brien, M.E. (2011). WEEKLY PACLITAXEL APPEARS ACTIVE AND WELL-TOLERATED IN THIRD AND FOURTH-LINE ADVANCED NSCLC PATIENTS. Journal of thoracic oncology, Vol.6 (6), pp. S1301-S1301.

Popat, S. Riley, R.D. Billingham, L.J. Hubner, R.A. (2011). EXCISION REPAIR CROSS-COMPLEMENTATION GROUP 1 (ERCC1) STATUS AND NON-SMALL CELL LUNG CANCER (NSCLC) OUTCOMES: A META-ANALYSIS OF PUBLISHED STUDIES AND RECOMMENDATIONS. Journal of thoracic oncology, Vol.6 (6), pp. S438-S439.

Popat, S. Gonzalez, D. Min, T. Swansbury, J. Dainton, M. Croud, J. Rice, A. Nicholson, A.G. (2011). ALK TRANSLOCATION IS ASSOCIATED WITH ALK IMMUNOREACTIVITY AND EXTENSIVE SIGNET-RING MORPHOLOGY IN PRIMARY LUNG ADENOCARCINOMA. Journal of thoracic oncology, Vol.6 (6), pp. S506-S507.

Leary, A. Gonzalez, D. Nicholson, A.G. Wotherspoon, A. Olansunkanmi, F. O'Brien, M. Popat, S. (2011). SAMPLE QUALITY CRITERIA FOR ROUTINE EGFR MUTATION SCREENING - PATHOLOGICAL FEATURES MAY BE MORE USEFUL THAN CLINICAL PHENOTYPE IN A UK POPULATION. Journal of thoracic oncology, Vol.6 (6), pp. S569-S570.

Waddell, T.S. Myerson, J. Reid, A. Ashley, S. Starling, N. Seet, J.-. Nimako, K. Popat, S. O'Brien, M.E. (2011). THE UK TWO WEEK RULE INITIATIVE IN LUNG CANCER - FIRST REPORT OF IMPACT ON DISEASE STAGE AND 5-YEAR SURVIVAL. Journal of thoracic oncology, Vol.6 (6), pp. S523-S524.

Pattenden, H. Deshmukh, M. Dusmet, M. Goldstraw, P. Lim, E. Jordan, S. Ladas, G. Popat, S. Rice, A. Von der Thusen, J. Nicholson, A.G. (2011). PERIPHERAL VERSUS CENTRAL RESECTED PRIMARY SQUAMOUS CELL CARCINOMAS OF THE LUNG - A REVIEW OF 526 CASES. Journal of thoracic oncology, Vol.6 (6), pp. S445-S446.

Tai, F.W. Khor, K.S. Popat, S. Beckles, M. Leung, M. Al-Sahaf, M. Lim, E. (2011). ONCOLOGISTS, PHYSICIANS AND SURGEONS OPINIONS ON THE PERCEIVED VALUE AND APPROPRIATENESS OF THE SPECIALITY TO INFORM PATIENTS ON ADJUVANT CHEMOTHERAPY AFTER RADICAL SURGERY FOR NON-SMALL CELL LUNG CANCER. Journal of thoracic oncology, Vol.6 (6), pp. S1334-S1334.

Myerson, J.S. Nimako, K. Moore, S. Karpathakis, A. Calderone, R. Popat, S. O'Brien, M. (2011). QUALITY OF LIFE ASSESSMENTS IN LUNG CANCER AND MESOTHELIOMA A COMPARISON OF QUESTIONNAIRES AND PHYSICIAN CONSULTATION - A POOR WORKMAN ALWAYS BLAMES HIS TOOLS?. Journal of thoracic oncology, Vol.6 (6), pp. S1206-S1207.

Freidin, M.B. Bhudia, N. Lim, E. Nicholson, A.G. Popat, S. Cookson, W.O. Moffatt, M.F. (2011). SAMPLE HANDLING AND PROCESSING ARE CRITICAL FACTORS INFLUENCING THE RESULTS OF WHOLE GENOME GENE EXPRESSION PROFILING IN LUNG CANCER TISSUES. Journal of thoracic oncology, Vol.6 (6), pp. S373-S374.

Patton, S. Thunnissen, E. Murray, S. Benlloch, S. Butler, R. Dietel, M. Filipits, M. Kerr, K.M. Normanno, N. Popat, S. Wallace, A. Stahel, R. Taron, M. Blackhall, F. (2011). A PILOT EXTERNAL QUALITY ASSURANCE SCHEME FOR SOMATIC EGFR MUTATION TESTING IN NON-SMALL CELL LUNG CANCER. Journal of thoracic oncology, Vol.6 (6), pp. S1510-S1511.

Calderone, R. Nimako, K. Leary, A. Popat, S. O’Brien, M.E. (2011). Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease – a short communication. European journal of cancer, Vol.47 (11), pp. 1603-1605.

Hubner, R.A. Goldstein, R. Mitchell, S. Jones, A. Ashley, S. O’Brien, M.E. Popat, S. (2011). Influence of co-morbidity on renal function assessment by Cockcroft–Gault calculation in lung cancer and mesothelioma patients receiving platinum-based chemotherapy. Lung cancer, Vol.73 (3), pp. 356-360.

Popat, S. Vieira de Araújo, A. Min, T. Swansbury, J. Dainton, M. Wotherspoon, A. Lim, E. Nicholson, A.G. O'Brien, M.E. (2011). Lung Adenocarcinoma with Concurrent Exon 19 EGFR Mutation and ALK Rearrangement Responding to Erlotinib. Journal of thoracic oncology, Vol.6 (11), pp. 1962-1963.

Zhao, D.B. Chandler, I. Chen, Z.M. Pan, H.C. Popat, S. Shao, Y.F. Houlston, R.S. (2011). Mismatch repair, minichromosome maintenance complex component 2, cyclin A, and transforming growth factor beta receptor type II as prognostic factors for colorectal cancer: results of a 10-year prospective study using tissue microarray analysis. Chinese med j-peking, Vol.124 (4), pp. 483-490. show abstract

Khor, K.S. Tai, D. Popat, S. Beckles, M. Leung, M. Al Sahaf, M. Lim, E.K. (2011). Oncologists', physicians' and surgeons' opinions on the perceived value and appropriateness of the speciality to inform patients on adjuvant chemotherapy after radical surgery for non-small cell lung cancer. Journal of clinical oncology, Vol.29 (15_suppl), pp. 7011-7011.

Khor, K.S. Tai, D. Popat, S. Beckles, M. Leung, M. Al Sahaf, M. Lim, E.K. (2011). Oncologists', physicians' and surgeons' opinions on the perceived value and appropriateness of the speciality to inform patients on adjuvant chemotherapy after radical surgery for non-small cell lung cancer. J clin oncol, Vol.29 (15_suppl), p. 7011. show abstract

7011 Background: The benefit of chemotherapy after surgery for lung cancer is established, but roles and responsibilities of discussing adjuvant chemotherapy are not established. Whilst risks are straight forward to convey, difficulties in conveying the benefit results from published hazard ratios as the benefit varies with stage and therefore needs to be calculated individually and conveyed in a language that is understood by the patient. METHODS: From 2010 to 2011, a survey was conducted of cancer physicians, oncologists and surgeons in the UK. Clinicians asked to rank the most appropriate speciality to discuss adjuvant chemotherapy with patients, to calculate expected survival given baseline survival probability of 80% and a hazard ratio of 0.80, and then surveyed for the additional expected gain in cohorts with a 5 year survival probability of 40%, 60% and 80% respectively before they would recommend adjuvant chemotherapy Results: A total of 202 responses were received from 27 surgeons, 77 physicians, 87 oncologists (11 unstated). The majority of 56% of surgeons, 79% of physicians and 61% of oncologists felt an oncologist as the most appropriate initial clinician to discuss adjuvant chemotherapy with patients after surgery. In total 33% of surgeons, 53% of physicians and 73% of oncologists were able to correctly calculate the expected survival of patients. When asked about perceived value before considering recommending adjuvant chemotherapy with 5 year survival probabilities of 40%, 60% and 80%, clinicians reported an expected a mean gain (SE) of 20.8% (2.7), 15.6% (2.4) and 13.2% (2.1) against an expected of 12%, 8% and 4% respectively with a hazard ratio of 0.80. CONCLUSIONS: Our survey suggest oncologists as the clinicians best able to calculate the individual benefit of adjuvant chemotherapy and the majority of specialities polled agreed oncologists as the most appropriate initial person to discuss adjuvant chemotherapy with patients after radical surgery for lung cancer. The perceived value prior to recommending adjuvant chemotherapy in clinicians greatly exceeds current published results..

Goldstein, R. Reid, F. Campbell, J. Popat, S. Benepal, T. (2010). Neurosurgery for brain metastases (BM) in the management of non-small cell lung cancer (NSCLC): A retrospective study of all cerebral metastasectornies at St George's Hospital London (SGH), 1999-2009. Lung cancer, Vol.67, pp. S38-S38.

Hubner, R. Goldstein, R. Mitchell, S. Jones, A. Ashley, S. O'Brien, M. Popat, S. (2010). Influence of co-morbidity on renal function estimation by Cockcroft Gault calculation in lung cancer and mesothelioma patients receiving platinum-based chemotherapy. Lung cancer, Vol.67, pp. S9-S9.

Lim, E. Baldwin, D. Beckles, M. Duffy, J. Entwisle, J. Faivre-Finn, C. Kerr, K. Macfie, A. McGuigan, J. Padley, S. Popat, S. Screaton, N. Snee, M. Waller, D. Warburton, C. Win, T. (2010). Guidelines on the radical management of patients with lung cancer. Thorax, Vol.65 (Suppl 3), pp. iii1-iii27.

Puglisi, M. Dolly, S. Faria, A. Myerson, J.S. Popat, S. O'Brien, M.E. (2010). Treatment options for small cell lung cancer – do we have more choice?. British journal of cancer, Vol.102 (4), pp. 629-638.

Forster, M. Enting, D. Nicholson, A.G. O’Brien, M. Popat, S. (2010). The combination of Young's syndrome and small cell lung cancer—A spiky connection?. Lung cancer, Vol.67 (3), pp. 372-375.

Nicholson, A.G. Gonzalez, D. Shah, P. Pynegar, M.J. Deshmukh, M. Rice, A. Popat, S. (2010). Refining the Diagnosis and EGFR Status of Non-small Cell Lung Carcinoma in Biopsy and Cytologic Material, Using a Panel of Mucin Staining, TTF-1, Cytokeratin 5/6, and P63, and EGFR Mutation Analysis. Journal of thoracic oncology, Vol.5 (4), pp. 436-441.

Calderone, R.G. Nimako, K. Leary, A.N. Popat, S. Kipps, E. O'Brien, M.N. (2010). USE OF ZOLEDRONIC ACID IN LUNG CANCER. Journal of thoracic oncology, Vol.5 (5), pp. S99-S100.

Brunetto, A.T. Carden, C.P. Myerson, J. Faria, A.L. Ashley, S. Popat, S. O'Brien, M.E. (2010). Modest Reductions in Dose Intensity and Drug-Induced Neutropenia have No Major Impact on Survival of Patients with Non-small Cell Lung Cancer Treated with Platinum-Doublet Chemotherapy. Journal of thoracic oncology, Vol.5 (9), pp. 1397-1403.

Myerson, J.S. Faria, A. Puglisi, M. Starling, N. Popat, S. O’Brien, M.E. (2010). The value of day 8 blood count in treatment decisions when using oral vinorelbine in non-small cell lung cancer. Lung cancer, Vol.69 (3), pp. 365-366.

Myerson, J.S. Iqbal, S.A. O’Brien, M.E. Popat, S. (2010). Supersensitive Mutation: Two Case Reports of Non–Small-Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Clinical lung cancer, Vol.11 (5), pp. E5-E8.

Trani, L. Myerson, J. Ashley, S. Young, K. Sheri, A. Hubner, R. Puglisi, M. Popat, S. O’Brien, M.E. (2010). Histology classification is not a predictor of clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine or gemcitabine combinations. Lung cancer, Vol.70 (2), pp. 200-204.

Benson, C. Kristeleit, R.S. Ashley, S. Dolly, S. Mikropoulos, C. O'Brien, M. Popat, S. (2010). Retrospective review of all patients with thymoma treated over the last 33 years at the Royal Marsden Hospital. Journal of clinical oncology, Vol.28 (15_suppl), pp. 7095-7095.

Irshad, S. Popat, S. Shah, R.N. Burbridge, S. Lal, R. Lang-Lazdunski, L. Viney, Z. Marsden, P. Barrington, S. Spicer, J.F. (2010). A phase II study of sorafenib in malignant mesothelioma with pharmacodynamic imaging using 18fdg-PET. Journal of clinical oncology, Vol.28 (15_suppl), pp. 7038-7038.

Myerson, J.S. Moore, S.A. Popat, S. O'Brien, M.E. (2010). Quality of Life Assessments in Lung Cancer - An evaluation of three questionnaires What's best for routine clinical practice?. American journal of respiratory and critical care medicine, Vol.181.

Faria, A. Myerson, J.S. Puglisi, M. Starling, N. Ashley, S. Popat, S. O'Brien, M.E. Bruzynski, P. (2009). The value of day 8 blood count in treatment decisions when using oral vinorelbine in non-small cell lung cancer (NSCLC) patients. Lung cancer, Vol.63, pp. S4-S4.

Benning, J. Starling, N. Myerson, J.S. Popat, S. Ashley, S. O'Brien, M.E. (2009). An audit of neutropaenia in patients with small cell lung carcinoma (SCLC) undergoing platinum-based chemotherapy – urgent need for specific SCLC guidelines. Lung cancer, Vol.63, pp. S13-S13.

Baird, R. Mikropoulos, C. Ashley, S. Killick, E. Myerson, J.S. Wotherspoon, A. O'Brien, M.E. Popat, S. Jackson-Jones, R. (2009). Audit of epidermal growth factor receptor (EGFR) expression by immunohistochemistry (IHC) using Dako and Ventana clones in non-small cell lung cancer (NSCLC). Lung cancer, Vol.63, pp. S2-S3.

O'Brien, M.E. Myerson, J.S. Popat, S. Puglisi, M. Starling, N. Trani, L. Bhupinder, S. Gary, C. Sue, A. (2009). The use of PET-CT scan in the assessment of response to Tarceva (erlotinib) in non small cell lung (NSCLC) cancer patients. Journal of thoracic oncology, Vol.4 (9), pp. S390-S391.

Dolly, S.O. Popat, S. (2009). Endocrine manifestations of malignancy. Medicine, Vol.37 (9), pp. 457-460.

Popat, S. Barbachano, Y. Ashley, S. Norton, A. O’Brien, M. (2008). Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer. Lung cancer, Vol.59 (2), pp. 227-231.

O'Brien, M.E. Yau, T. Coward, J. Hughes, S. Papadopoulos, P. Popat, S. Norton, A. Ashley, S. (2008). Time and Chemotherapy Treatment Trends in the Treatment of Elderly Patients (Age≥70 Years) with Non-small Cell Lung Cancer. Clinical oncology, Vol.20 (2), pp. 142-147.

Hughes, S. Barbachano, Y. Ashley, S. Yap, Y.-. Popat, S. Allen, M. Della-Rovere, U.Q. Johnston, S. Smith, I. O’Brien, M. (2008). Time Trends in the Outcome of Elderly Patients with Breast Cancer. The breast journal, Vol.14 (2), pp. 158-163.

Brunetto, A. Carden, C.P. Ashley, S. Baird, R. Myerson, J. Kristeleit, R. Montes, A. Popat, S. O'Brien, M. (2008). Dose intensity in advanced non-small cell lung cancer. Lung cancer, Vol.60, pp. S20-S20.

Ho, G.F. Popat, S. Nutting, C. (2008). Induction and concurrent chemoradiotherapy for non-small cell lung cancer (NSCLC) using cisplatin and vinorelbine. Lung cancer, Vol.60, pp. S18-S18.

Carden, C.P. Myerson, J.S. Popat, S. Montes, A. Larkin, J.M. Benson, M.J. O'Brien, M.E. (2008). Good Vibrations and the Power of Positron Thinking: Positron Emission Tomography and Endoscopic Ultrasound in Staging of Mesothelioma—Two Case Reports. Journal of thoracic oncology, Vol.3 (5), pp. 539-541.

Popat, S. Smith, I.E. (2008). Therapy Insight: anthracyclines and trastuzumab—the optimal management of cardiotoxic side effects. Nature clinical practice oncology, Vol.5 (6), pp. 324-335.

Sirohi, B. Arnedos, M. Popat, S. Ashley, S. Nerurkar, A. Walsh, G. Johnston, S. Smith, I.E. (2008). Platinum-based chemotherapy in triple-negative breast cancer. Annals of oncology, Vol.19 (11), pp. 1847-1852.

Drilon, A.D. Popat, S. Bhuchar, G. D'Adamo, D.R. Keohan, M.L. Fisher, C. Antonescu, C.R. Singer, S. Brennan, M.F. Judson, I. Maki, R.G. (2008). Extraskeletal Myxoid Chondrosarcoma A Retrospective Review From 2 Referral Centers Emphasizing Long-term Outcomes With Surgery and Chemotherapy. Cancer, Vol.113 (12), pp. 3364-3371. show abstract

Dernedde, U. Chan, S. Sykes, H. Oakley, C. Larkin, J. Popat, S. Gilbert, D. Jones, L. Chowdhury, S. (2008). South West London Cancer Network (SWLCN) audit of patients with chemotherapy-induced febrile neutropenia (CIFN). Journal of clinical oncology, Vol.26 (15_suppl), pp. 20653-20653.

Sirohi, B. Arnedos, M. Popat, S. Ashley, S. Nerurkar, A. Walsh, G. Johnston, S. Smith, I.E. (2008). Platinum-based chemotherapy in triple-negative (TN) breast cancer. Journal of clinical oncology, Vol.26 (15_suppl), pp. 1051-1051.

Popat, S. Zhao, D.B. Chen, Z.M. Pan, H.C. Sha, Y.F. Chandler, I. Houlston, R.S. (2007). Relationship between chromosome 18q status and colorectal cancer prognosis: A prospective, blinded analysis of 280 patients. Anticancer res, Vol.27 (1B), pp. 627-633. show abstract

Tjellström, B. Stenhammar, L. Högberg, L. Fälth-Magnusson, K. Magnusson, K.-. Midtvedt, T. Sundqvist, T. Houlston, R. Popat, S. Norin, E. (2007). Gut microflora associated characteristics in first-degree relatives of children with celiac disease. Scandinavian journal of gastroenterology, Vol.42 (10), pp. 1204-1208.

Popat, S. Zhao, D.B. Chen, Z.M. Pan, H.C. Sha, Y.F. Chandler, I. Houlston, R.S. (2007). Relationship between chromosome 18q status and colorectal cancer prognosis: A prospective, blinded analysis of 280 patients (vol 27, pg 627, 2007). Anticancer res, Vol.27 (2), pp. 1231-1231.

Popat, S. Hughes, S. Papadopoulos, P. Wilkins, A. Moore, S. Priest, K. Meehan, L. Norton, A. O’Brien, M. (2007). Recurrent responses to non-small cell lung cancer brain metastases with erlotinib. Lung cancer, Vol.56 (1), pp. 135-137.

Sirohi, B. Ashley, S. Norton, A. Popat, S. Hughes, S. Papadopoulos, P. Priest, K. O'Brien, M. (2007). Early Response to Platinum-Based First-Line Chemotherapy in Non-small Cell Lung Cancer May Predict Survival. Journal of thoracic oncology, Vol.2 (8), pp. 735-740.

Wilkins, A. Popat, S. Hughes, S. O’Brien, M. (2007). Malignant pleural mesothelioma: Two cases in first degree relatives. Lung cancer, Vol.57 (3), pp. 407-409.

Hubner, R.A. Muir, K.R. Liu, J.F. Logan, R.F. Grainge, M. Armitage, N. Shepherd, V. Popat, S. Houlston, R.S. United Kingdom Colorectal Aden, (2006). Genetic variants of UGT1A6 influence risk of colorectal adenoma recurrence. Clin cancer res, Vol.12 (21), pp. 6585-6589. show abstract

Yau, T. Ashley, S. Popat, S. Norton, A. Matakidou, A. Coward, J. O'Brien, M.E. (2006). Time and chemotherapy treatment trends in the treatment of elderly patients (age ⩾70 years) with small cell lung cancer. British journal of cancer, Vol.94 (1), pp. 18-21.

Popat, S. Wort, R. Houlston, R.S. (2006). Inter-relationship between microsatellite instability, thymidylate synthase expression, and p53 status in colorectal cancer: implications for chemoresistance. Bmc cancer, Vol.6, show abstract

Popat, S. Smith, I.E. (2006). Breast cancer. Update on cancer therapeutics, Vol.1 (2), pp. 187-210.

Popat, S. Lopez, J. Chan, S. Waters, J. Rutter, D. E Hill, M. (2006). Palliative treatments for patients with inoperable gastroesophageal cancers. International journal of palliative nursing, Vol.12 (7), pp. 306-317.

Popat, S. Chen, Z. Zhao, D. Pan, H. Hearle, N. Chandler, I. Shao, Y. Aherne, W. Houlston, R.S. (2006). A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. Ann oncol, Vol.17 (12), pp. 1810-1817. show abstract

Johnson, V. (2005). Exon 3 -catenin mutations are specifically associated with colorectal carcinomas in hereditary non-polyposis colorectal cancer syndrome. Gut, Vol.54 (2), pp. 264-267.

Popat, S. Smith, I.E. (2005). Re: Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis. Jnci: journal of the national cancer institute, Vol.97 (11), pp. 858-858.

Popat, S. Wort, R. Houlston, R.S. (2005). Relationship between thyrnidylate synthase (TS) genotype and TS expression: A tissue microarray analysis of colorectal cancers. Int j surg pathol, Vol.13 (2), pp. 127-133. show abstract

Popat, S. O??Brien, M. (2005). Chemotherapy strategies in the treatment of small cell lung cancer. Anti-cancer drugs, Vol.16 (4), pp. 361-372.

Popat, S. Houlston, R.S. (2005). A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur j cancer, Vol.41 (14), pp. 2060-2070. show abstract

Popat, S. Matakidou, A. Houlston, R.S. (2005). Thymidylate synthase expression in colorectal cancer: The never-ending story - In reply. J clin oncol, Vol.23 (9), pp. 2108-2109.

Popat, S. Hubner, R. Houlston, R.S. (2005). Systematic review of microsatellite instability and colorectal cancer prognosis. J clin oncol, Vol.23 (3), pp. 609-618. show abstract

Popat, S. Houlston, R.S. (2005). Re: Reporting recommendations for tumor marker prognostic studies (REMARK). J natl cancer i, Vol.97 (24), pp. 1855-1855.

POPAT, S. (2005). Systematic review of microsatellite instability and colorectal cancer prognosis. J clin oncol, Vol.23, pp. 609-618.

Popat, S. Matakidou, A. Houlston, R.S. (2004). Thymidylate synthase expression and prognosis in colorectal cancer: A systematic review and meta-analysis. J clin oncol, Vol.22 (3), pp. 529-536. show abstract

Matakidou, A. Hamel, N. Popat, S. Henderson, K. Kantemiroff, T. Harmer, C. Clarke, S.E. Houlston, R.S. Foulkes, W.D. (2004). Risk of non-medullary thyroid cancer influenced by polymorphic variation in the thyroglobulin gene. Carcinogenesis, Vol.25 (3), pp. 369-373. show abstract

Sumpter, K. Harper-Wynne, C. Yeoh, C. Popat, S. Ashley, S. Norton, A. O’Brien, M. (2004). Is the second line data on the use of docetaxel in non-small cell lung cancer reproducible?. Lung cancer, Vol.43 (3), pp. 369-370.

Popat, S. Hubner, R. Houlston, R.S. (2004). A meta-analysis of microsatellite instability and colorectal cancer prognosis. J clin oncol, Vol.22 (14_suppl), p. 9576. show abstract

Popat, S. Nicholson, A.G. Fisher, C. Harmer, C. Moskovic, E. Murday, V.A. Houlston, R.S. (2004). Pulmonary masses presenting 11 years after abdominal surgery - Diagnosis: Pulmonary hyalinizing granuloma. Respiration, Vol.71 (3), pp. 295-297.

Hodgson, S.V. Popat, S. (2003). Polymorphic sequence variants in medicine: a challenge and an opportunity. Clinical medicine, Vol.3 (3), pp. 260-264.

Popat, S. Stone, J. Houlston, R.S. (2003). Allelic imbalance in colorectal cancer at the CRAC1 locus in early-onset colorectal cancer. Cancer genet cytogen, Vol.145 (1), pp. 70-73. show abstract

Popat, S. Hearle, N. Wixey, J. Hogberg, L. Bevan, S. Lim, W. Stenhammar, L. Houlston, R.S. (2002). Analysis of the CTLA4 gene in Swedish coeliac disease patients. Scand j gastroentero, Vol.37 (1), pp. 28-31. show abstract

Popat, S. Hearle, N. Hogberg, L. Braegger, C.P. O'Donoghue, D. Falth-Magnusson, K. Holmes, G.K. Howdle, P.D. Jenkins, H. Johnston, S. Kennedy, N.P. Kumar, P.J. Logan, R.F. Marsh, M.N. Mulder, C.J. Naluai, A.T. Sjoberg, K. Stenhammar, L. Walters, J.R. Jewell, D.P. Houlston, R.S. (2002). Variation in the CTLA4/CD28 gene region confers an increased risk of coeliac disease. Ann hum genet, Vol.66, pp. 125-137. show abstract

Popat, S. Hearle, N. Bevan, S. Holmes, G.K. Howdle, P.D. Hogberg, L. Braegger, C.P. O'Donoghue, D. Falth-Magnusson, K. Jenkins, H. Johnston, S. Kennedy, N.P. Kumar, P. Logan, R.F. Marsh, M.N. Mulder, C.J. Sjoberg, K. Stenhammar, L. Walters, J.R. Jewell, D.P. Houlston, R.S. (2002). A genetic analysis of coeliac disease. Gut, Vol.50, pp. A92-A92.

Popat, S. Bevan, S. Braegger, C.P. Busch, A. O'Donoghue, D. Falth-Magnusson, K. Godkin, A. Hogberg, L. Holmes, G. Hosie, K.B. Howdle, P.D. Jenkins, H. Jewell, D. Johnston, S. Kennedy, N.P. Kumar, P. Logan, R.F. Love, A.H. Marsh, M.N. Mulder, C.J. Sjoberg, K. Stenhammar, L. Walker-Smith, J. Houlston, R.S. (2002). Genome screening of coeliac disease. J med genet, Vol.39 (5), pp. 328-331.

Popat, S. Hearle, N. Bevan, S. Hogberg, L. Stenhammar, L. Houlston, R.S. (2002). Mutational analysis of CD28 in coeliac disease. Scand j gastroentero, Vol.37 (5), pp. 536-539. show abstract

Popat, S. Hogberg, L. McGuire, S. Green, H. Bevan, S. Stenhammar, L. Houlston, R.S. (2001). Germline mutations in TGM2 do not contribute to coeliac disease susceptibility in the Swedish population. Eur j gastroen hepat, Vol.13 (12), pp. 1477-1479. show abstract

Popat, S. Stone, J. Coleman, G. Marshall, G. Peto, J. Frayling, I. Houlston, R. (2000). Prevalence of the APC E1317Q variant in colorectal cancer patients. Cancer letters, Vol.149 (1-2), pp. 203-206.

Bevan, S. Popat, S. Braegger, C.P. Busch, A. O'Donoghue, D. Falth-Magnusson, K. Ferguson, A. Godkin, A. Hogberg, L. Holmes, G. Hosie, K.B. Howdle, P.D. Jenkins, H. Jewell, D. Johnston, S. Kennedy, N.P. Kerr, G. Kumar, P. Logan, R.F. Love, A.H. Marsh, M. Mulder, C.J. Sjoberg, K. Stenhammer, L. Walker-Smith, J. Marossy, A.M. Houlston, R.S. (1999). Contribution of the MHC region to the familial risk of coeliac disease. J med genet, Vol.36 (9), pp. 687-690. show abstract

Bevan, S. Catovsky, D. Marossy, A. Matutes, E. Popat, S. Antonovic, P. Bell, A. Berrebi, A. Gaminara, E.J. Quabeck, K. Ribeiro, I. Mauro, F.R. Stark, P. Sykes, H. van Dongen, J. Wimperis, J. Wright, S. Yuille, M.R. Houlston, R.S. (1999). Linkage analysis for ATM in familial B cell chronic lymphocytic leukaemia. Leukemia, Vol.13 (10), pp. 1497-1500. show abstract

Bevan, S. Popat, S. Houlston, R.S. (1999). Relative power of linkage and transmission disequilibrium test strategies to detect non-HLA linked coeliac disease susceptibility genes. Gut, Vol.45 (5), pp. 668-671. show abstract

Brown, S.A. Popat, S. Carr, R. (1997). An unusual cause of chest pain. Postgraduate medical journal, Vol.73 (866), pp. 825-827.

Brown, S.A. Popat, S. Carr, R. (1997). An unusual cause of chest pain - Thrombotic thrombocytopenic purpura presenting with chest pain. Postgraduate medical journal, Vol.73 (866), pp. 825-827.

Hubner, R.A. Riley, R.D. Billingham, L.J. Popat, S. Excision Repair Cross-Complementation Group 1 (ERCC1) Status and Lung Cancer Outcomes: A Meta-Analysis of Published Studies and Recommendations. Plos one, Vol.6 (10), pp. e25164-e25164.

Pender, A. Garcia-Murillas, I. Rana, S. Cutts, R.J. Kelly, G. Fenwick, K. Kozarewa, I. Gonzalez de Castro, D. Bhosle, J. O’Brien, M. Turner, N.C. Popat, S. Downward, J. Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach. Plos one, Vol.10 (9), pp. e0139074-e0139074.

Popat, S. Yap, T. Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer. Pharmacogenomics and personalized medicine, , pp. 285-285.

Minchom, A. Thavasu, P. Ahmad, Z. Stewart, A. Georgiou, A. O’Brien, M.E. Popat, S. Bhosle, J. Yap, T.A. de Bono, J. Banerji, U. A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments. Plos one, Vol.12 (10), pp. e0186106-e0186106.

True. Leukemia, Vol.13 (10), pp. 1497-1500.

Minchom, A. Mak, D. Gunapala, R. Walder, D. Kumar, R. Yousaf, N. Hodgkiss, A. Bhosle, J. Popat, S. O’Brien, M.E. A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma. Plos one, Vol.14 (11), pp. e0225509-e0225509.

Zhang, Y.Z. Brambilla, C. Molyneaux, P.L. Rice, A. Robertus, J.L. Jordan, S. Lim, E. Lang‐Lazdunski, L. Begum, S. Dusmet, M. Anikin, V. Beddow, E. Finch, J. Asadi, N. Popat, S. Le Quesne, J. Husain, A.N. Cookson, W.O. Moffatt, M.F. Nicholson, A.G. Presence of pleomorphic features but not growth patterns improves prognostic stratification of epithelioid malignant pleural mesothelioma by 2‐tier nuclear grade. Histopathology, .

Book Chapters

Popat, S. Treatment of Cancer. Nutrition and Cancer. (pp. 27-44). John Wiley & Sons, Ltd., ISBN: 9781405190428.

Conferences

Griesinger, F.Camidge, D.R.Kim, H.R.Ahn, M.-.Yang, J.C.Han, J.Y.Hochmair, M.Lee, H.Delmonte, A.Garcia Compelo, M.R.Kim, D.-.Felip, E.Califano, R.Spire, A.Gettinger, S.N.Tiseo, M.Lin, H.M.Ni, Q.Zhang, P.Popat, S. (2020). Updated Results from the Phase 3 ALTA-1L Trial of Brigatinib (BRG) vs. Crizotinib (CRZ) in ALK Inhibitor-Naive Advanced ALK plus NSCLC, ONCOLOGY RESEARCH AND TREATMENT, Vol.43, p.232.

Molina-Vila, M.-.Stahel, R.A.Dafni, U.Jordana-Ariza, N.Balada-Bel, A.Garzón-Ibáñez, M.García-Peláez, B.Mayo-de-las-Casas, C.Felip, E.Curioni Fontecedro, A.Gautschi, O.Peters, S.Massutí, B.Palmero, R.Ponce Aix, S.Carcereny, E.Früh, M.Pless, M.Popat, S.Cuffe, S.Bidoli, P.Kammler, R.Roschitzki-Voser, H.Tsourti, Z.Karachaliou, N.Rosell, R. (2020). Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial, Journal of Thoracic Oncology, Vol.15 (3), pp.416-425.

Gomes, F.Tokaca, N.Yip, K.Ghosh, S.Newsom-Davis, T.Greystoke, A.Mills, H.Ahmed, S.Harle, A.S.Ayre, G.Shah, R.Popat, S.Blackhall, F.H.Summers, Y. (2019). Brigatinib experience on the ALK project, Annals of Oncology, Vol.30, p.ii53.

Califano, R.Hochmair, M.J.Gridelli, C.Delmonte, A.Garcia Campelo, M.R.Bearz, A.Griesinger, F.Morabito, A.Felip, E.Ghosh, S.Tiseo, M.Haney, J.Kerstein, D.Popat, S.Camidge, D.R. (2019). Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial, ANNALS OF ONCOLOGY, Vol.30, p.41.

Januszewski, A.Zhang, Y.Z.Chang, W.-.Laggner, U.Bowman, A.Adefila-Ideozu, T.Vivanco, I.Moffatt, M.F.Cookson, W.O.Gupta, N.P.Nicholson, A.G.Bowcock, A.Popat, S. (2019). Impact of MET variants on PD-L1 expression in pleomorphic lung carcinoma, Annals of Oncology, Vol.30, p.ii1.

Lang-Lazdunski, L.Zhang, Y.Z.Popat, S.O'Brien, M.Steele, J.Newsom-Davis, T.Scherpereel, A.Bouchaab, H.Rice, A.Nicholson, A. (2019). MA05.01 Second or Third Line Anti-PD-1 Therapy After Multimodality Therapy Including Total Pleurectomy in Malignant Pleural Mesothelioma, Journal of Thoracic Oncology, Vol.14 (10), pp.S264-S265.

Middleton, G.Popat, S.Fletcher, P.Summers, Y.Greystoke, A.Gilligan, D.Cave, J.O'Rourke, N.Brewster, A.Toy, E.Spicer, J.Savage, J.Sharpe, R.Yap, T.Swanton, C.Billingham, L. (2019). PL02.09 National Lung Matrix Trial (NLMT): First Results from an Umbrella Phase II Trial in Advanced Non-Small Cell Lung Cancer (NSCLC), Journal of Thoracic Oncology, Vol.14 (10), p.S7.

Campelo, R.G.Lin, H.Perol, M.Jahanzeb, M.Popat, S.Zhu, Y.Zhang, P.Camidge, D.R. (2019). P1.01-124 Health-Related Quality of Life (HRQoL) Data in a Phase 3 Study of First-Line Brigatinib vs Crizotinib in NSCLC (ALTA-1L), Journal of Thoracic Oncology, Vol.14 (10), pp.S411-S412.

Popat, S.Liu, G.Lu, S.Song, G.Samnotra, V.Yang, J.C. (2019). Phase III ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) that progressed on crizotinib (CRZ), ANNALS OF ONCOLOGY, Vol.30.

Zhang, Y.Z.Brambilla, C.Rice, A.Robertus, J.Jordan, S.Lim, E.Lang-Lazdunski, L.Popat, S.Moffatt, M.Cookson, W.Nicholson, A. (2019). MA12.02 Growth Patterns in Epithelioid Malignant Pleural Mesothelioma: A Clinicopathological Review of 614 Cases Over 15 Years, Journal of Thoracic Oncology, Vol.14 (10), pp.S295-S296.

Zhang, Y.Z.Brambilla, C.Rice, A.Robertus, J.Jordan, S.Lim, E.Lang-Lazdunski, L.Popat, S.Husain, A.Moffatt, M.Cookson, W.Nicholson, A. (2019). P1.06-08 WDPM-Like but Not Cribriform as Secondary Growth Patterns Modify Survival in Epithelioid Malignant Pleural Mesothelioma, Journal of Thoracic Oncology, Vol.14 (10), pp.S480-S481.

Lang-Lazdunski, L.Zhang, Y.Z.Popat, S.O'Brien, M.Steele, J.Newsom-Davis, T.Lal, R.Nicholson, A. (2019). P2.06-05 Multimodality Therapy Using Total Pleurectomy in Malignant Pleural Mesothelioma: Long-Term Outcomes in 150 Consecutive Cases, Journal of Thoracic Oncology, Vol.14 (10), p.S757.

Nastase, A.Mandal, A.Lu, S.K.Gennatas, S.Anbunathan, H.Edwards, M.Morris-Rosendahl, D.Taylor, A.N.Rintoul, R.C.Lim, E.Popat, S.Nicholson, A.Lathrop, M.Bowcock, A.Moffatt, M.Cookson, W. (2019). MA23.10 Low Number of Mutations and Frequent Co-Deletions of CDKN2A and IFN Type I Characterize Malignant Pleural Mesothelioma, Journal of Thoracic Oncology, Vol.14 (10), p.S345.

Fennell, D.Hudka, M.Darlison, L.Lord, K.Bzura, A.Dzialo, J.Pritchard, C.Harber, J.Takata, T.Popat, S.Krebs, M.Nolan, L.Greystoke, A.Richards, C.Wells-Jordan, P.Branson, A.Gaba, A.Bhundia, V.Scotland, M.Mohamed, S.Dawson, A.Poille, C.Cowley, C.Walter, H.King, A.Thomas, A. (2019). P2.06-02 Mesothelioma Stratified Therapy (MiST): A Phase IIA Umbrella Trial for Accelerating the Development of Precision Medicines, Journal of Thoracic Oncology, Vol.14 (10), pp.S755-S756.

Popat, S. (2019). IBS23.02 Oncological Treatment of Omd in Daily Clinical Practice, Journal of Thoracic Oncology, Vol.14 (10), p.S115.

Mandal, A.Nastase, A.Lu, S.K.Gennatas, S.Anbunathan, H.Edwards, M.Morris-Rosendahl, D.Taylor, A.N.Rintoul, R.C.Lim, E.Popat, S.Nicholson, A.Bowcock, A.Lathrop, M.Moffatt, M.Cookson, W. (2019). MA23.11 Analysis of Immune Phenotype Composition in Malignant Pleural Mesothelioma (MPM) Using Bulk RNA Sequencing, Journal of Thoracic Oncology, Vol.14 (10), pp.S345-S346.

O'Byrne, K.Yang, J.C.Wu, Y.Hirsh, V.Yamamoto, N.Popat, S.Tamiya, A.Märten, A.Schuler, M. (2019). P2.14-60 Afatinib in EGFR Mutation-Positive NSCLC: Activity in Patients with Brain Metastases, and Impact on CNS Progression/Spread, Journal of Thoracic Oncology, Vol.14 (10), p.S855.

Novello, S.Brustugun, O.T.Cadranel, J.Griesinger, F.Hochmair, M.J.Perol, M.Popat, S.Bent-Ennakhil, N.Kruhl, C.Felip, E. (2019). Brigatinib in ALK TKI-pretreated ALK plus metastatic non-small cell lung cancer (mNSCLC): The use via expanded access to brigatinib (UVEA-Brig) study, ANNALS OF ONCOLOGY, Vol.30, p.636.

Popat, S.Curioni-Fontecedro, A.Polydoropoulou, V.Shah, R.O'Brien, M.Pope, A.Fisher, P.Spicer, J.Roy, A.Gilligan, D.Gautschi, O.Nadal, E.Janthur, W.-.Lopez Castro, R.Garcia Campelo, R.Roschitzki-Voser, H.Ruepp, B.Rusakiewicz, S.Peters, S.Stahel, R.A. (2019). A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial, ANNALS OF ONCOLOGY, Vol.30, p.931.

Januszewski, A.Zhang, Y.Z.Brambilla, C.Chang, W.Laggner, U.Bowman, A.Adefila-Ideozu, T.Vivanco, I.Cookson, W.Moffatt, M.Nicholson, A.Popat, S.Bowcock, A. (2019). P1.04-63 Correlation of Mutations in TP53, CDKN2A and PIK3CA with VISTA Expression in Pleomorphic Lung Carcinoma, Journal of Thoracic Oncology, Vol.14 (10), pp.S465-S466.

Yang, J.C.Kim, H.R.Ahn, M.-.Han, J.-.Hochmair, M.J.Lee, K.H.Delmonte, A.Campelo, M.R.Kim, D.-.Felip, E.Califano, R.Spira, A.Gettinger, S.Tiseo, M.Haney, J.Kerstein, D.Popat, S.Camidge, D.R. (2019). Brigatinib (BRG) vs Crizotinib (CRZ) in Patients (Pts) With ALK Inhibitor-Naive Advanced ALK+ NSCLC from ALTA-1L, Annals of Oncology, Vol.30, p.vi83.

Camidge, R.Kim, H.R.Ahn, M.-.Yang, J.C.Han, J.-.Hochmair, M.J.Lee, K.H.Delmonte, A.Garcia Campelo, M.R.Kim, D.-.Griesinger, F.Felip, E.Califano, R.Spira, A.Gettinger, S.Tiseo, M.Ni, Q.Zhang, P.Popat, S. (2019). Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK1 NSCLC: Updated results from the phase III ALTA-1L trial, ANNALS OF ONCOLOGY, Vol.30.

Ahn, M.-.Kim, H.Yang, J.C.Han, J.-.Lee, J.S.Hochmair, M.J.Li, J.Y.Chang, G.-.Lee, K.H.Gridelli, C.Campelo, R.G.Delmonte, A.Kim, D.-.Kerstein, D.Ni, Q.Zhang, P.Popat, S.Camidge, D.R. (2019). Brigatinib (BRG) versus crizotinib (CRZ) in Asian versus non-Asian patients (pts) in the phase III ALTA-1L trial., JOURNAL OF CLINICAL ONCOLOGY, Vol.37 (15).

Campelo, R.G.Lin, H.M.Perol, M.Jahanzeb, M.Popat, S.Zhu, Y.Zhang, P.Camidge, D.R. (2019). Health-related quality of life (HRQoL) results from ALTA-1L: Phase 3 study of brigatinib vs crizotinib as first-line (1L) ALK therapy in advanced ALK plus non-small cell lung cancer (NSCLC)., JOURNAL OF CLINICAL ONCOLOGY, Vol.37 (15).

Lee, R.Low, N.Popat, S. (2019). In whom could we diagnose second primary lung cancers ‘early’?, Presented at ERS International Congress 2019 abstracts, Lung cancer, .

Dolly, S.O.Brandao, M.Taylor, C.Gunapala, R.Myerson, J.Waddell, T.Popat, S.Bhosle, J.O'Brien, M. (2018). The impact of the UK Government 'two week rule' (TWR) on lung cancer stage and 5-year survival - a decade of experience from the Royal Marsden Hospital (RMH), LUNG CANCER, Vol.115, p.S18.

Tokaca, N.Pouptsis, A.Karapanagiotou, E.Spicer, J.Halkyard, E.Blackhall, F.Summers, Y.Greystoke, A.Bhosle, J.Jones, A.Newsom-Davis, T.Nicolson, M.O'Brien, M.Yousaf, N.Popat, S. (2018). Retrospective analysis of outcomes in UK patients with advanced NSCLC and ROS1 rearrangement, LUNG CANCER, Vol.115, pp.S44-S45.

Kumar, R.Joharatnam, N.Pealing, J.Walder, D.P.Milner-Watts, C.L.Yousaf, N.Bhosle, J.Popat, S.O'Brien, M. (2018). Lactate dehydrogenase and neutrophil-lymphocyte ratio as clinical predictors of outcome to PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer, LUNG CANCER, Vol.115, p.S40.

Milner-Watts, C.L.Kumar, R.Gunapala, R.Walder, D.P.Minchom, A.Yousef, N.Popat, S.Bhosle, J.O'Brien, M. (2018). Less frequent monitoring of response in patients with advanced thoracic malignancies receiving palliative chemotherapy, does not adversely impact patient care, LUNG CANCER, Vol.115, pp.S42-S43.

Nastase, A.Gennatas, S.Mandal, A.Liu, K.Edwards, M.Morris-Rosendahl, D.Rintoul, R.Lim, E.Anbunathan, H.Popat, S.Lathrop, M.Nicholson, A.Moffatt, M.Bowcock, A.M.Cookson, W. (2018). Targeted next-generation sequencing of malignant pleural mesothelioma identifies recurrent NRAS oncogene mutations, LUNG CANCER, Vol.115, p.S26.

Lindsay, C.R.Shaw, E.Popat, S.Blyth, K.G.Walker, I.Chaturvedi, A.Dicks, C.Rassl, D.Taniere, P.Johnson, P.W.Wallace, W.A.Blackhall, F.Nicholson, A.G. (2018). KRAS Subtypes in non-small cell lung cancer (NSCLC) within Phase I of the Cancer Research UK Stratified Medicine Programme (SMP1), LUNG CANCER, Vol.115, p.S6.

Mandal, A.Gennatas, S.Liu, K.Nastase, A.Edwards, M.Morris-Rosendahl, D.Rintoul, R.Lim, E.Anbunathan, H.Popat, S.Lathrop, M.Nicholson, A.G.Bowcockl, A.M.Moffatt, M.Cookson, W. (2018). Copy number variations in malignant pleural mesothelioma reveal novel regions of genomic imbalances, LUNG CANCER, Vol.115, p.S27.

Laggner, U.Adefila-Ideozu, T.Lim, E.Popat, S.Thompson, L.Macmahon, S.Bowman, A.D.Nicholson, A. (2018). Limiting ROS-1 immunohistochemistry to a population of patients either aged 55 years or younger, or never smokers of any age, as a method for cost-efficient screening ROS-1 gene rearrangements, MODERN PATHOLOGY, Vol.31, p.737.

Pavlakis, N.Grosso, F.Steele, N.Nowak, A.Novello, S.Popat, S.Greillier, L.Reck, M.Kitzing, T.Scagliotti, G. (2018). 213O Nintedanib + pemetrexed/cisplatin in malignant pleural mesothelioma (MPM): Phase II biomarker data from the LUME Meso study, Journal of Thoracic Oncology, Vol.13 (4), p.S128.

Tokaca, N.O'Brien, M.Bhosle, J.Yousaf, N.Kumar, R.Popat, S.Walder, D. (2018). 149P Real-world outcomes with first-line afatinib in EGFR mutant NSCLC adenocarcinoma: A single centre experience exploring effects of dose-reduction, Journal of Thoracic Oncology, Vol.13 (4), pp.S89-S90.

Yang, J.C.Wu, Y.-.Hirsh, V.O'Byrne, K.Yamamoto, N.Popat, S.Tamiya, A.Märten, A.Schuler, M. (2018). 143PD Competing central nervous system or systemic progression analysis for patients with EGFR mutation-positive NSCLC receiving afatinib in LUX-Lung 3, 6, and 7, Journal of Thoracic Oncology, Vol.13 (4), pp.S84-S85.

Lang-Lazdunski, L.Tokaca, N.Lal, K.R.Steele, J.Newsom-Davis, T.Landau, D.Spicer, J.Popat, S. (2018). 216PD Should radical surgery be performed in non-epithelioid malignant pleural mesothelioma?, Journal of Thoracic Oncology, Vol.13 (4), p.S130.

O'Byrne, K.Yang, J.C.Wu, Y.-.Hirsh, V.Yamamoto, N.Popat, S.Tamiya, A.Maerten, A.Schuler, M. (2018). Central Nervous System or Systemic Progression Analysis for EGFR Mutation-Positive NSCLC Patients Receiving Afatinib in LUX-Lung 3, 6, and 7, ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol.14, p.69.

Yang, J.C.Wu, Y.Hirsh, V.O’Byrne, K.Yamamoto, N.Popat, S.Tamiya, A.Kaen, D.Märten, A.Schuler, M. (2018). P06 Competing CNS or Systemic Progression Analysis for EGFR Mutation-Positive NSCLC Patients on Afatinib in LUX-Lung 3, 6, and 7, Journal of Thoracic Oncology, Vol.13 (9), p.S163.

Camidge, R.Kim, H.R.Ahn, M.Yang, J.C.Han, J.Lee, J.Hochmair, M.Li, J.Y.Chang, G.Lee, K.Gridelli, C.Delmonte, A.Garcia Campelo, M.R.Kim, D.Bearz, A.Griesinger, F.Morabito, A.Felip, E.Califano, R.Ghosh, S.Spira, A.Gettinger, S.Tiseo, M.Haney, J.Kerstein, D.Popat, S. (2018). PL02.03 Brigatinib vs Crizotinib in Patients With ALK Inhibitor-Naive Advanced ALK+ NSCLC: First Report of a Phase 3 Trial (ALTA-1L), Journal of Thoracic Oncology, Vol.13 (10), pp.S184-S185.

Zhang, Y.Z.Adefila-Ideozu, T.Bowman, A.Januszewski, A.Popat, S.Jordan, S.Robertus, J.Rice, A.Moffatt, M.Cookson, W.Nicholson, A. (2018). P2.06-41 Differentiating Sarcomatoid Mesothelioma from Pleomorphic Carcinoma and Chest Wall Sarcoma Using GATA-3/MUC4/BAP1 IHC, Journal of Thoracic Oncology, Vol.13 (10), pp.S758-S759.

Gautschi, O.Drilon, A.Milia, J.Lusque, A.Mhanna, L.Li, B.Sabari, J.Cortot, A.Besse, B.Mezquita, L.Solomon, B.Thai, A.Couraud, S.Veillon, R.Mascaux, C.Barlesi, F.Van Den Heuvel, M.Schouten, R.Wakelee, H.Mah, A.Camidge, D.R.Ng, T.Peled, N.Lilach, Y.Popat, S.Ou, S.Zhu, V.Velcheti, V.Curioni Fontecedro, A.Akhoundova, D.Früh, M.Zalcman, G.Gounant, V.Novello, S.Bironzo, P.Felip, E.Martinez-Marti, A.Moro-Sibilot, D.Rosell, R.Karachaliou, N.Schuler, M.Wiesweg, M.Diebold, J.Mazieres, J. (2018). MA04.03 Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations: New Results from the Global IMMUNOTARGET Registry, Journal of Thoracic Oncology, Vol.13 (10), p.S367.

Popat, S.Januszewski, A.Hughes, L.O'Brien, M.Ahmad, T.Lewanski, C.Dernedde, U.Jankowska, P.Mulatero, C.Shah, R.Hicks, J.Geldart, T.Cominos, M.Gray, G.Spicer, J.Bell, K.Roitt, S.Howarth, K.Cinelli, M.Green, E.Morris, C.Ngai, Y.Hackshaw, A. (2018). P1.13-17 Multicentre Phase II Trial of First-Line Afatinib in Patients with Suspected/Confirmed EGFR Mutant NSCLC: ctDNA and Long-Term Efficacy, Journal of Thoracic Oncology, Vol.13 (10), pp.S588-S589.

Popat, S. (2018). ES06.02 Integrating New Systemic Therapy into Trials in OMD, Journal of Thoracic Oncology, Vol.13 (10), p.S200.

Januszewski, A.Zhang, Y.Z.Chang, W.Laggner, U.Bowman, A.Adefila-Ideozu, T.Cookson, W.Moffatt, M.Nicholson, A.Bowcock, A.Popat, S. (2018). MA21.03 Heterogeneity in MET Copy Number and Intratumoural Subsets in Pleomorphic Lung Carcinoma: Implications for MET Directed Therapy in NSCLC, Journal of Thoracic Oncology, Vol.13 (10), p.S430.

Scagliotti, G.Gaafar, R.Nowak, A.Nakano, T.Van Meerbeeck, J.Popat, S.Vogelzang, N.Grosso, F.Aboelhassan, R.Jakopovic, M.Ceresoli, G.Taylor, P.Orlandi, F.Fennell, D.Novello, S.Scherpereel, A.Von Wangenheim, U.Kim, M.Barrueco, J.Tsao, A. (2018). PL02.09 Nintedanib + Pemetrexed/Cisplatin in Patients with Unresectable MPM: Phase III Results from the LUME-Meso Trial, Journal of Thoracic Oncology, Vol.13 (10), p.S186.

Middleton, G.Brock, K.Summers, Y.Connibear, J.Shah, R.Ottensmeier, C.Shaw, P.Ming-Lee, S.Popat, S.Barrie, C.Barone, G.Mant, R.Savage, J.S.Billingham, L. (2018). Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): Results of the PePS2 trial, Annals of Oncology, Vol.29, p.viii497.

Escriu, C.Sallam, M.del Carpio, L.P.Tokaca, N.Solway, L.Shah, R.Fouzia, A.Ghafoor, Q.Popat, S.Postmus, P.E. (2018). Afatinib dose intensity and clinical efficacy in advanced EGFR-mutated non-small cell lung cancer: UK multicentre real-life data, Annals of Oncology, Vol.29, p.viii526.

Popat, S.Kim, H.R.Ahn, M.-.Yang, J.C.Han, J.-.Hochmair, M.J.Lee, K.H.Delmonte, A.Garcia Campelo, M.R.Kim, D.-.Griesinger, F.Felip, E.Califano, R.Spira, A.I.Gettinger, S.Tiseo, M.Haney, J.Kerstein, D.Camidge, D.R. (2018). Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial, Annals of Oncology, Vol.29, p.viii746.

O'Byrne, K.Yang, J.C.Wu, Y.-.Hirsh, V.Yamamoto, N.Popat, S.Tamiya, A.Maerten, A.Schuler, M. (2018). Afatinib for patients with EGFR mutation-positive (EGFRm plus ) NSCLC: Activity in patients with baseline brain metastases and impact on the rate of central nervous system (CNS) progression or spread, ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol.14, pp.159-160.

Popat, S.Grosso, F.Steele, N.Nowak, A.K.Novello, S.Greillier, L.Reck, M.John, T.Taylor, P.Leighl, N.B.Ceresoli, G.L.Sørensen, J.B.Pavlakis, N.Planchard, D.Hughes, B.G.Mazieres, J.Socinski, M.A.Buchner, H.Barrueco, J.Scagliotti, G.V. (2018). Tumor burden (TB) and treatment exposure (TE) in patients (pts) with malignant pleural mesothelioma (MPM) receiving nintedanib (N)/placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in phase II of the LUME-Meso study., Journal of Clinical Oncology, Vol.36 (15_suppl), p.8566.

Pavlakis, N.Grosso, F.Steele, N.L.Nowak, A.K.Novello, S.Popat, S.Greillier, L.Reck, M.John, T.Taylor, P.Leighl, N.B.Ceresoli, G.L.Sørensen, J.B.Planchard, D.Hughes, B.G.Mazieres, J.Socinski, M.A.von Wangenheim, U.Barrueco, J.Scagliotti, G.V. (2018). Association between progression-free survival (PFS) rate (PFSR) and overall survival (OS) in LUME-Meso, a study of nintedanib (N) vs. placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in patients (pts) with malignant pleural mesothelioma (MPM)., Journal of Clinical Oncology, Vol.36 (15_suppl), p.8568.

Zauderer, M.G.Szlosarek, P.Le Moulec, S.Popat, S.Taylor, P.Planchard, D.Scherpereel, A.Jahan, T.Koczywas, M.Forster, M.Cameron, R.B.Peikert, T.Campbell, C.Sapir, I.McDonald, A.Oei, C.Clawson, A.Roche, M.Fennell, D.A. (2018). Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation., Journal of Clinical Oncology, Vol.36 (15_suppl), p.8515.

Mazieres, J.Drilon, A.E.Mhanna, L.Milia, J.Lusque, A.Cortot, A.B.Mezquita, L.Thai, A.Couraud, S.Veillon, R.Mascaux, C.Schouten, R.Neal, J.W.Ng, T.L.Frueh, M.Peled, N.Gounant, V.Popat, S.Zhu, V.W.Gautschi, O. (2018). Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget)., Journal of Clinical Oncology, Vol.36 (15_suppl), p.9010.

Kordbacheh, T.Chan, C.Faivre-Finn, C.Franks, K.McDonald, F.Forster, M.Mendes, R.Quezade, S.Dovedi, S.Ralph, C.Popat, S.Harrington, K.Melcher, A.Popple, A.Illidge, T. (2017). PD-RAD:A translational study investigating PD-L1 expression after radiotherapy for non-small cell lung cancer (NSCLC), LUNG CANCER, Vol.103, pp.S78-S79.

Tokaca, N.Espinasse, A.Petruckevitch, A.Ellis, S.Yousaf, N.Bhosle, J.O'Brien, M.Popat, S. (2017). A phase I/II trial of combination nab-paclitaxel and nintedanib or nab-paclitaxel and placebo in relapsed NSCLC adenocarcinoma (N3), LUNG CANCER, Vol.103, pp.S77-S78.

Kordbacheh, T.Chan, C.Bossons, A.Franks, K.McDonald, F.Forster, M.Mendes, R.Quezada, S.Dovedi, S.Ralph, C.Popat, S.Harrington, K.Melcher, A.Popple, A.Illidge, T.Faivre-Finn, C. (2017). PARIS: A phase I study of pembrolizumab anti-PD-1 monoclonal antibody in combination with radiotherapy (RT) in locally advanced non-small cell lung cancer (NSCLC), LUNG CANCER, Vol.103, pp.S75-S76.

Tokaca, N.Crawford, M.S.Greystoke, A.Appel, W.Lal, R.Steele, N.Ali, C.Bezecny, P.Fernando, S.Karapanagiotou, E.Skailes, G.Dorey, N.Harrow, S.Bhosle, J.Khan, O.Newsom-Davis, T.Spicer, J.Toy, L.O'Brien, M.Gunapala, R.Lu, S.K.Popat, S. (2017). Outcomes with nintedanib and docetaxel in patients with relapsed NSCLC adenocarcinoma treated within the UK Nintedanib Individual Patient Supply programme, LUNG CANCER, Vol.103, pp.S32-S33.

Gennatas, S.Lu, S.K.Anbunathan, H.Popat, S.O'Brien, M.Lim, E.Fernandez, A.M.Benepal, T.Nicholson, A.G.Lathrop, M.Moffatt, M.Cookson, W.Bowcock, A.M. (2017). Somatic BAP1 and NF2 mutations in pleural malignant mesothelioma and their correlation with clinical phenotype, LUNG CANCER, Vol.103, pp.S25-S26.

Tokaca, N.Barth, S.O'Brien, M.Bhosle, J.Fotiadis, N.Wotherspoon, A.Thompson, L.Popat, S. (2017). Adequacy of image-guided rebiopsies for molecular retesting in advanced NSCLC: a single centre experience, LUNG CANCER, Vol.103, pp.S15-S16.

Gennatas, S.Anbunathan, H.Bowman, A.Fernandez, A.M.Nicholson, A.G.Popat, S.Bowcock, A.M. (2017). Somatic and germline mutations in thymic epithelial tumours and their correlation with histological and clinical phenotypes, LUNG CANCER, Vol.103, p.S52.

Minchom, A.Punwani, R.Filshie, J.Bhosle, J.Nimako, K.Myerson, J.Gunapala, R.Popat, S.O'Brien, M. (2017). Anxiolytic Effect of Acupuncture in a Phase II Study of Acupuncture and Morphine for Dyspnea in Lung Cancer and Mesothelioma, JOURNAL OF THORACIC ONCOLOGY, Vol.12 (1), pp.S1415-S1416.

Popat, S.Hughes, L.O'Brien, M.Ahmad, T.Lewanski, C.Dernedde, U.Jankowska, P.Mulatero, C.Shah, R.Hicks, J.Geldart, T.Cominos, M.Gray, G.Spicer, J.Bell, K.Ngai, Y.Hackshaw, A. (2017). Afatinib Benefits Patients with Confirmed/Suspected EGFR Mutant NSCLC, Unsuitable for Chemotherapy (TIMELY Phase II Trial), JOURNAL OF THORACIC ONCOLOGY, Vol.12 (1), pp.S1215-S1216.

Kumar, R.Bhosle, J.Yap, T.Minchom, A.Walder, D.Ali, Z.Ratnayake, G.Yousaf, N.Popat, S.Gunapala, R.O'Brien, M. (2017). Optimal Frequency of Tumor Response Evaluation during Palliative Chemotherapy in the Management of Patients with Advanced Thoracic Cancers, JOURNAL OF THORACIC ONCOLOGY, Vol.12 (1), p.S1522.

Grosso, F.Steele, N.Novello, S.Nowak, A.Popat, S.Greillier, L.John, T.Leighl, N.Reck, M.Taylor, P.Pavlakis, N.Sorensen, J.B.Planchard, D.Ceresoli, G.Hughes, B.Mazieres, J.Socinski, M.Mueller, M.Von Wangenheim, U.Loembe, A.B.Morsli, N.Barrueco, J.Scagliotti, G. (2017). Nintedanib plus Pemetrexed/Cisplatin in Patients with MPM: Phase II Findings from the Placebo-Controlled LUME-Meso Trial, JOURNAL OF THORACIC ONCOLOGY, Vol.12 (1), pp.S329-S330.

Gautschi, O.Milia-Baron, J.Filleron, T.Wolf, J.Carbone, D.Owen, D.Camidge, D.R.Narayanan, V.Doebele, R.Besse, B.Remon, J.Janne, P.Awad, M.Peled, N.Byoung, C.-.Karp, D.Van den Heuve, M.Wakelee, H.Nea, J.Mok, T.Yang, J.C.Ou, S.-.Pa, G.Froesch, P.Zalcman, G.Gandara, D.R.Riess, J.Velcheti, V.Zeidler, K.Diebold, J.Fruh, M.Michels, S.Monnet, I.Popat, S.Rosell, R.Karachaliou, N.Rothschild, S.Shih, J.-.Warth, A.Muley, T.Cabillic, F.Mazieres, J.Drilon, A. (2017). Global RET Registry (GLORY): Activity of RET-Directed Targeted Therapies in RET-Rearranged Lung Cancers, JOURNAL OF THORACIC ONCOLOGY, Vol.12 (1), pp.S435-S436.

Gandara, D.R.Popat, S.Melosky, B. (2017). Systemic Therapy for Advanced Oncogene-Driven NSCLC, JOURNAL OF THORACIC ONCOLOGY, Vol.12 (1), pp.S51-S52.

Yang, J.C.Ou, S.-.De Petris, L.Gadgeel, S.Gandhi, L.Kim, D.-.Barlesi, F.Govindan, R.Dingemans, A.-.Crino, L.Lena, H.Popat, S.Ahn, J.S.Dansin, E.Golding, S.Bordogna, W.Balas, B.Morcos, P.N.Zeaiter, A.Shaw, A. (2017). Pooled Efficacy and Safety Data from Two Phase II Studies (NP28673 and NP28761) of Alectinib in ALK plus Non-Small-Cell Lung Cancer (NSCLC), JOURNAL OF THORACIC ONCOLOGY, Vol.12 (1), pp.S1170-S1171.

Kumar, R.Walder, D.P.Bhosle, J.Yap, T.A.O'Brien, M.E.Popat, S.Thompson, L.Macmahon, S.Palma, J.de Castro, D.G. (2017). Diagnostic EGFR testing with ctDNA versus tumour in patients with advanced non-small cell lung cancer (NSCLC): The Royal Marsden experience, ANNALS OF ONCOLOGY, Vol.28.

Popat, S.Gaafar, R.Nowak, A.Tsao, A.Van Meerbeeck, J.Vogelzang, N.Nakano, T.Velema, D.Morsli, N.Scagliotti, G. (2017). LUME-Meso: Randomised phase II/III study of nintedanib (N) 1 pemetrexed/cisplatin (PEM/CIS) followed by maintenance N or placebo (P) in chemo-naive patients with malignant pleural mesothelioma (MPM), ANNALS OF ONCOLOGY, Vol.28.

Popat, S.Ardizzoni, A.Ciuleanu, T.Cobo Dols, M.Laktionov, K.Szilasi, M.Califano, R.Carcereny Costa, E.Griffiths, R.Paz-Ares, L.Szczylik, C.Corral, J.Isla, D.Jassem, J.Appel, W.Van Meerbeeck, J.Wolf, J.Jiang, J.Molife, L.R.Felip Font, E. (2017). Nivolumab in previously treated patients with metastatic squamous NSCLC: Results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged >= 70 years and with poor performance status, ANNALS OF ONCOLOGY, Vol.28.

Wood, J.Stevens, A.-.Kano, Y.Nevin, J.Popat, S.Wiseman, T.Droney, J. (2017). Proactive referral to palliative care: Model of a new integrated palliative care and oncology service, ANNALS OF ONCOLOGY, Vol.28.

Novello, S.Nowak, A.K.Grosso, F.Steele, N.Popat, S.Greillier, L.John, T.Leighl, N.B.Reck, M.Pavlakis, N.Sorensen, J.B.Planchard, D.Ceresoli, G.L.Hughes, B.Mazieres, J.Socinski, M.A.von Wangenheim, U.Barrueco, J.Morsli, N.Scagliotti, G. (2017). Overall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N) plus pemetrexed/cisplatin (PEM/CIS) vs placebo (P) plus PEM/CIS in chemo-naive patients (pts) with malignant pleural mesothelioma (MPM), ANNALS OF ONCOLOGY, Vol.28.

Grosso, F.Steele, N.Novello, S.Nowak, A.Popat, S.Greillier, L.von Wangenheim, U.Morsli, N.Barrueco, J.Scagliotti, G. (2017). Nintedanib plus pemetrexed/cisplatin in patients with MPM: Phase II findings from the placebo-controlled LUME-Meso trial, Annals of Oncology, Vol.28, p.ix74.

Popat, S.Ardizzoni, A.Ciuleanu, T.Dols, M.C.Laktionov, K.Szilasi, M.Califano, R.Costa, E.C.Griffiths, R.Paz-Ares, L.Szczylik, C.Jaime, J.C.Isla, D.Jassem, J.Appel, W.van Meerbeeck, J.Wolf, J.Jiang, J.Molife, L.R.Felip, E. (2017). Nivolumab in Patients With Previously TreatedMetastatic Squamous Non-Small Cell Lung Cancer (NSCLC): Results of A European Single-Arm, Phase II Trial (CHECKMATE 171) Including Patients Aged >= 70 Years or With Poor Performance Status, ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol.13, pp.149-150.

Novello, S.Nowak, A.Grosso, F.Steele, N.Popat, S.Greillier, L.John, T.Leighl, N.Reck, M.Pavlakis, N.Sorensen, J.B.Planchard, D.Ceresoli, G.L.Hughes, B.Mazieres, J.Socinski, M.Von Wangenheim, U.Barrueco, J.Morsli, N.Scagliotti, G. (2017). OA03.06 Overall Survival and Forced Vital Capacity in the LUME-Meso Study of Nintedanib + Pemetrexed/Cisplatin in Patients with Mesothelioma, Journal of Thoracic Oncology, Vol.12 (11), p.S1555.

Scagliotti, G.Gaafar, R.Nowak, A.Tsao, A.Vogelzang, N.Kuribayashi, K.Velema, D.Morsli, N.Popat, S. (2017). PS04.03 LUME-Meso Phase II/III Study: Nintedanib + Pemetrexed/Cisplatin in Chemo-Naïve Patients with Malignant Pleural Mesothelioma, Journal of Thoracic Oncology, Vol.12 (11), p.S1577.

Bainbridge, H.Dunlop, A.Mcquaid, D.Colgan, R.Popat, S.Yousaf, N.Bhosle, J.O’Brien, M.Ahmed, M.Locke, I.Mcdonald, F. (2017). MA 09.09 Isotoxic Dose-Escalated Radiotherapy (RT) in Non-Small Cell Lung Cancer (NSCLC) with Deep Inspiration Breath Hold (DIBH), Journal of Thoracic Oncology, Vol.12 (11), p.S1838.

Gennatas, S.Mandal, A.Nicholson, A.Popat, S.Bowcock, A. (2017). OA 03.02 Comprehensive Characterization of Thymic Epithelial Tumor Subtypes Through an Analysis of Somatic Mutations and Copy Number Alterations, Journal of Thoracic Oncology, Vol.12 (11), p.S1749.

Tsao, A.Vogelzang, N.Nowak, A.Popat, S.Gaafar, R.Van Meerbeeck, J.Nakano, T.Barrueco, J.Morsli, N.Scagliotti, G. (2017). LUME-Meso Phase II/III Study: Nintedanib plus Pemetrexed/Cisplatin in Chemo-Naive Patients with Malignant Pleural Mesothelioma, JOURNAL OF THORACIC ONCOLOGY, Vol.12 (11), pp.S2020-S2021.

Nowak, A.Grosso, F.Steele, N.Novello, S.Popat, S.Greillier, L.John, T.Leighl, N.Reck, M.Pavlakis, N.Sørensen, J.B.Planchard, D.Ceresoli, G.Hughes, B.Mazieres, J.Socinski, M.Salnikov, A.Kitzing, T.Braunger, J.Pietzko, K.Scagliotti, G. (2017). MA 19.03 Nintedanib + Pemetrexed/Cisplatin in Malignant Pleural Mesothelioma (MPM): Phase II Biomarker Data from the LUME-Meso Study, Journal of Thoracic Oncology, Vol.12 (11), p.S1884.

Yang, J.C.Reckamp, K.Kim, Y.Novello, S.Smit, E.Lee, J.Su, W.Akerley, W.Blakely, C.Bazhenova, L.Chiari, R.Hsia, T.Golsorkhi, T.Despain, D.Shih, D.Rolfe, L.Popat, S.Wakelee, H. (2017). P2.03-058 Tiger-3: A Phase 3 Randomized Study of Rociletinib Vs Chemotherapy in EGFR-mutated Non-small Cell Lung Cancer (NSCLC), Journal of Thoracic Oncology, Vol.12 (11), p.S2397.

Popat, S. (2017). MTE 09.02 Symptom Experiences and Symptom Clusters in Advanced Lung Cancer, Journal of Thoracic Oncology, Vol.12 (11), pp.S1640-S1641.

Gennatas, S.Mandal, A.Robertus, J.Bowman, A.Nicholson, A.Popat, S.Bowcock, A. (2017). B7-H3 Protein Expression in Thymic Epithelial Tumor Subtypes and Its Association with PD-L1 and Clinical Characteristics, JOURNAL OF THORACIC ONCOLOGY, Vol.12 (11), pp.S2066-S2067.

Kumar, R.Brandao, M.Joharatnam, N.Pealing, J.Walder, D.Minchom, A.Milner-Watts, C.Moorcraft, S.Y.Turkes, F.Yousaf, N.Bhosle, J.Popat, S.O'Brien, M. (2017). Early Clinical Predictors of Progressive Disease or Non-Response to PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer, JOURNAL OF THORACIC ONCOLOGY, Vol.12 (11), p.S2147.

Minchom, A.Gunapala, R.Walder, D.Kumar, R.Bhosle, J.Popat, S.Yousaf, N.O'Brien, M. (2017). Study of Plasma Homocysteine as a Marker of Toxicity and Depression in Patients Treated with Pemetrexed-Based Chemotherapy, JOURNAL OF THORACIC ONCOLOGY, Vol.12 (11), p.S1961.

Walder, D.Punwani, R.Gunapala, R.Kumar, R.Minchom, A.Bhosle, J.Popat, S.Yousaf, N.O’Brien, M. (2017). P3.12-003 Optimized Inhaler Therapy Is Superior to Supportive Care Alone for Dyspnea in Patients with Coexisting COPD and Lung Cancer, Journal of Thoracic Oncology, Vol.12 (11), pp.S2314-S2315.

Tiseo, M.Popat, S.Gettinger, S.N.Peters, S.Haney, J.Kerstein, D.Camidge, D.R. (2017). Design of ALTA-1L (ALK in lung cancer trial of brigatinib in first-line), a randomized phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)-naive patients (pts) with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)., Journal of Clinical Oncology, Vol.35 (15_suppl), p.TPS9098.

Nowak, A.K.Grosso, F.Steele, N.Novello, S.Popat, S.Greillier, L.John, T.Leighl, N.B.Reck, M.Pavlakis, N.Soerensen, J.B.Planchard, D.Ceresoli, G.L.Hughes, B.G.Mazieres, J.Socinski, M.A.Velema, D.von Wangenheim, U.Morsli, N.Scagliotti, G.V. (2017). Mature overall survival (OS) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM)., Journal of Clinical Oncology, Vol.35 (15_suppl), p.8506.

Zalcman, G.Peters, S.Mansfield, A.S.Jahan, T.M.Popat, S.Scherpereel, A.Hu, W.Selvaggi, G.Baas, P. (2017). Checkmate 743: A phase 3, randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma., Journal of Clinical Oncology, Vol.35 (15_suppl), p.TPS8581.

Kordbacheh, T.Kumar, R.Biondo, A.Tan, R.Yap, T.Popat, S.Bhosle, J.O'Brien, M.E. (2016). 47 Completion of the clinical audit cycle for delivery of molecular testing service for patients with non-small-cell lung cancer referred to the Royal Marsden, Lung Cancer, Vol.91, p.S17.

Minchom, A.R.Punwani, R.Filshie, J.Bhosle, J.Nimako, K.Gunapala, R.Popat, S.O'Brien, M.E. (2016). 163 A randomised study comparing the effectiveness of acupuncture (A) or morphine (M) versus the combination (AM) for the relief of dyspnoea in patients with advanced non small cell lung cancer and mesothelioma, Lung Cancer, Vol.91, p.S59.

Dumas, L.Macklin-Doherty, A.Wu, X.O'Brien, M.E.Popat, S.Yap, T.Bhosle, J. (2016). 72 The Royal Marsden NHS Foundation Trust experience of maintenance pemetrexed following first-line cisplatin/pemetrexed in advanced non-squamous lung cancer, Lung Cancer, Vol.91, p.S26.

Bainbridge, H.Toms, C.Kilburn, L.Popat, S.Bliss, J.Mcdonald, F. (2016). 141 HALT trial: stereotactic radiotherapy for oligo-progressive disease (OPD) in oncogene-addicted lung tumours – results of a national trial feasibility questionnaire, Lung Cancer, Vol.91, p.S51.

Leung, M.Freidina, D.Nicholson, A.Rice, A.Freidin, M.Fernandez, A.M.Popat, S.Lim, E. (2016). 1 A comparative analysis of cancer hotspot mutation profiles in circulating tumour cells, circulating tumour DNA and matched primary lung tumour, Lung Cancer, Vol.91, p.S1.

Smyth, E.C.Turner, N.C.Pearson, A.Peckitt, C.Chau, I.Watkins, D.J.Starling, N.Rao, S.Gillbanks, A.Kilgour, E.Sumpter, K.A.Smith, N.R.Cutts, R.Rooney, C.Thomas, A.L.Ajaz, M.A.Chua, S.Brown, G.Popat, S.Cunningham, D. (2016). Phase II study of AZD4547 in FGFR amplified tumours: Gastroesophageal cancer (GC) cohort pharmacodynamic and biomarker results., Journal of Clinical Oncology, Vol.34 (4_suppl), p.154.

De Ruysscher, D.Pujol, J.-.Popat, S.Reck, M.Le Pechoux, C.Liston, A.Speiser, D.Coukos, G.Kammler, R.Dafni, O.Tsourti, Z.Roschitzki, H.Finlayson, M.Piguet, A.-.Ruepp, B.Maibach, R.Stahel, R.A.Peters, S. (2016). STIMULI: A randomised open-label phase II trial of consolidation with nivolumab and ipilimumab in limited-stage SCLC after standard of care chemo-radiotherapy conducted by ETOP and IFCT, ANNALS OF ONCOLOGY, Vol.27.

Felip, E.Van Meerbeeck, J.Wolf, J.Ardizzoni, A.Li, A.Srinivasan, S.Popat, S. (2016). 193TiP: CheckMate 171: A multicenter phase 2 trial of nivolumab (nivo) in patients (pts) with stage IIIB/IV squamous cell (SQ) NSCLC who have received ≥1 prior systemic treatment, Journal of Thoracic Oncology, Vol.11 (4), p.S141.

Felip, E.Van Meerbeeck, J.Wolf, J.Ardizzoni, A.Li, A.Srinivasan, S.Popat, S. (2016). CheckMate 171: A multicenter phase 2 trial of nivolumab (nivo) in patients (pts) with stage IIIB/IV squamous cell (SQ) NSCLC who have received >= 1 prior systemic treatment, JOURNAL OF THORACIC ONCOLOGY, Vol.11 (4), p.S141.

Scagliotti, G.V.Gaafar, R.Nowak, A.Vogelzang, N.J.Von Wangenheim, U.Morsli, N.Velema, D.Popat, S. (2016). P2.01: LUME-MeSO: Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma, Journal of Thoracic Oncology, Vol.11 (10), p.S216.

Popat, S.Tiseo, M.Gettinger, S.Peters, S.Haney, J.Kerstein, D.Camidge, D.R. (2016). ALTA-1L (ALK in lung cancer trial of BrigAtinib in 1st Line): A randomized, phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)–naive, advanced anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC), Annals of Oncology, Vol.27, p.vi448.

Scagliotti, G.V.Gaafar, R.Nowak, A.Vogelzang, N.J.Von Wangenheim, U.Morsli, N.Velema, D.Popat, S. (2016). LUME-MeSO: Phase II/III Study of Nintedanib plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma, JOURNAL OF THORACIC ONCOLOGY, Vol.11 (10), p.S216.

Rosell, R.Karachaliou, N.Giménez-Capitán, A.Codony-Servat, C.Gautschi, O.Felip, E.Curioni-Fontecedro, A.Peters, S.Ponce-Aix, S.Früh, M.Pless, M.Popat, S.Cuffe, S.Bidoli, P.Favaretto, A.Kammler, R.Dafni, U.Tsourti, Z.Molina-Vila, M.A.Stahel, R.A. (2016). Abstract 269: The role of BRCA1 and AEG1 mRNA expression in advanced non-small-cell lung cancer (NSCLC) patients (p) with EGFR activating and pretreatment T790M mutations receiving the combination of erlotinib plus bevacizumab (E+B) in the BELIEF trial, Presented at Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA, Experimental and Molecular Therapeutics, .

Pender, A.Rana, S.Garcia-Murillas, I.Cutts, R.Gonzalez, D.O'Brien, M.Bhosle, J.Turner, N.C.Popat, S.Downward, J. (2016). Simultaneous EGFR mutation detection and copy number assessment in circulating tumour DNA (ctDNA) to inform molecular methods of therapy resistance and plasma ctDNA content in lung adenocarcinoma., Journal of Clinical Oncology, Vol.34 (15_suppl), p.e23027.

Yang, J.C.Popat, S.Novello, S.Groen, H.J.Perol, M.Felip, E.Griesinger, F.Reckamp, K.L.Lee, J.-.Smit, E.F.Blakely, C.M.Akerley, W.L.Kim, Y.-.Bazhenova, L.Califano, R.Hall, R.D.Georgiou, P.Isaacson, J.D.Golsorkhi, T.Wakelee, H.A. (2016). TIGER-3: A phase 3 multinational open-label randomized study of rociletinib vs investigator-choice chemotherapy in patients (pts) with epidermal growth factor receptor mutant-positive (EGFRm) non-small cell lung cancer (NSCLC) progressing on prior EGFR tyrosine kinase inhibitor (TKI) therapy and doublet chemotherapy., Journal of Clinical Oncology, Vol.34 (15_suppl), p.TPS9106.

Gennatas, S.Montero Fernandez, A.Bowman, A.Ronquillo, J.Nicholson, A.G.Popat, S.Bowcock, A. (2016). Expression of PD-L1, PD-L2 and PD-1 in thymic epithelial tumours (TETs)., Journal of Clinical Oncology, Vol.34 (15_suppl), p.e20107.

Scagliotti, G.V.Gaafar, R.M.Nowak, A.K.Van Meerbeeck, J.P.Vogelzang, N.J.von Wangenheim, U.Loembe, A.-.Morsli, N.Velema, D.Popat, S. (2016). Lume-meso: A double-blind, randomized, phase II/III study of nintedanib (N) + pemetrexed (P)/cisplatin (C) followed by maintenance N versus placebo + P/C followed by maintenance placebo for patients with unresectable malignant pleural mesothelioma (MPM)., Journal of Clinical Oncology, Vol.34 (15_suppl), p.TPS8574.

Yang, J.C.Ou, S.-.De Petris, L.Gadgeel, S.M.Gandhi, L.Kim, D.-.Barlesi, F.Govindan, R.Dingemans, A.-.Crino, L.Lena, H.Popat, S.Ahn, J.S.Dansin, E.Golding, S.Bordogna, W.Balas, B.Morcos, P.N.Zeaiter, A.H.Shaw, A.T. (2016). Efficacy and safety of alectinib in ALK+ non-small-cell lung cancer (NSCLC): Pooled data from two pivotal phase II studies (NP28673 and NP28761)., Journal of Clinical Oncology, Vol.34 (15_suppl), p.e20507.

Viola, P.Popat, S.Khan, O.Moule, R.Polychronis, A.Stokoe, J.Dickson, J.Montero Fernandez, A.Amat Villegas, I.Yancheva, S.Gonzalez de Castro, D.Nicholson, A.G. (2015). 83: A review of the first 10 months of screening selected patients for the ALK translocation using immunohistochemistry, and their subsequent treatment, Lung Cancer, Vol.87, pp.S32-S33.

Middleton, G.Billingham, L.Crack, L.Popat, S.Walker, I. (2015). 187: National Lung Matrix Trial: multi-drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer, Lung Cancer, Vol.87, pp.S69-S70.

Brock, K.Billingham, L.Crack, L.Popat, S.Middleton, G. (2015). 186: Forecasting patient recruitment for time-to-event analysis in National Lung Matrix Trial, Lung Cancer, Vol.87, p.S69.

Pender, A.Garcia-Murillas, I.Rana, S.de Castro, D.G.Turner, N.Popat, S.Downward, J. (2015). Abstract 2408: A novel multiplex droplet digital PCR approach to KRAS mutation detection in circulating tumor DNA, Presented at Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA, Clinical Research (Excluding Clinical Trials), .

Stahel, R.A.Dafni, U.Gautschi, O.Felip, E.Curioni-Fontecedro, A.Peters, S.Massutí, B.Cardenal, F.Aix, S.P.Früh, M.Pless, M.Popat, S.Kotsakis, A.Cuffe, S.Bidoli, P.Favaretto, A.Carcereny, E.Sanchez Ronco, M.Molina, M.A.Rosell, R. (2015). 3BA A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial, European Journal of Cancer, Vol.51, pp.S711-S712.

Popat, S.Felip, E.Cobo, M.Fulop, A.Dayen, C.Trigo, J.M.Gregg, R.Waller, C.F.Gordon, J.Lorence, R.Wang, B.Chand, V.K.Hirsh, V. (2015). 3085 Second-line afatinib vs erlotinib in patients with advanced squamous cell carcinoma (SCC) of the lung: patient-reported outcome (PRO) data from the global LUX-Lung 8 (LL8) Phase III trial, European Journal of Cancer, Vol.51, pp.S626-S627.

O'Brien, M.E.Minchom, A.R.Punwani, R.Bhosle, J.Nimako, K.Gunapala, R.Popat, S.Filshie, J. (2015). Randomised Study of Acupuncture, Morphine and Combination in NSCLC/Mesothelioma, JOURNAL OF THORACIC ONCOLOGY, Vol.10 (9), pp.S366-S367.

Kumar, R.Lo, K.Minchom, A.R.Sharp, A.Davidson, M.Gunapala, R.Yap, T.Bhosle, J.Popat, S.O'Brien, M.E. (2015). A Phase 1b Trial of the Combination of Capecitabine and Erlotinib in Advanced Lung Cancer, JOURNAL OF THORACIC ONCOLOGY, Vol.10 (9), pp.S547-S548.

Lu, S.K.Anbunathan, H.Popat, S.O'Brien, M.E.Lim, E.Fernandez, A.M.Nicholson, A.G.Lathrop, M.Bowcock, A.M.Moffatt, M.F.Cookson, W.O. (2015). Molecular Landscape of Malignant Mesothelioma from Whole Exome Sequencing, JOURNAL OF THORACIC ONCOLOGY, Vol.10 (9), p.S253.

Yang, J.C.Popat, S.Bazhenova, L.Blakely, C.M.Dichman, R.Felip, E.Griesinger, F.Groen, H.J.Gurubhagavatula, S.Leach, J.W.Novello, S.Perol, M.Patel, R.Reckamp, K.Georgiou, P.Miyamoto, E.Isaacson, J.Wakelee, H.A. (2015). TIGER-3: A Phase 3 Open-Label, Randomized Study of Rociletinib vs Chemotherapy in NSCLC, JOURNAL OF THORACIC ONCOLOGY, Vol.10 (9), p.S430.

Leung, M.Freidin, M.Freidina, D.Popat, S.Nicholson, A.Rice, A.Fernandez, A.M.Lim, E. (2015). A Comparative Analysis of Cancer Hotspot Mutation Profiles in Circulating Tumour Cells, Circulating Tumour DNA and Matched Primary Lung Tumour, JOURNAL OF THORACIC ONCOLOGY, Vol.10 (9), p.S604.

Viola, P.Devaraj, A.Lim, E.Luciano, G.Popat, S.Nicholson, A.G. (2015). Pathology-Imaging Agreement in Distinguishing Separate Primary Tumours and Intrapulmonary Metastasis in Staging of Multiple Lung Cancers, JOURNAL OF THORACIC ONCOLOGY, Vol.10 (9), pp.S261-S262.

Besse, B.Menis, J.Adam, J.Berghmans, T.Cufer, T.Dziadziuszko, R.Felip, E.Finn, S.P.Lacroix, L.Mazieres, J.Melgaard, P.Novello, S.Peters, S.Popat, S.Reck, M.Smit, E.Vansteenkiste, J.Hasan, B.Steuve, J.Varin, E.Lacombe, D.Stahel, R. (2015). SPECTAlung: Screening Patients with Thoracic Tumors for Efficient Clinical Trial Access, JOURNAL OF THORACIC ONCOLOGY, Vol.10 (9), pp.S706-S707.

Viola, P.Maurya, M.Croud, J.Gazdova, J.Suleman, N.Lim, E.Popat, S.Rice, A.Fernandez, A.M.De Castro, D.G.Nicholson, A.G. (2015). A Validation Study for the Use of ROS-1 Immunohistochemistry in Screening for ROS-1 Translocations in Lung Cancer, JOURNAL OF THORACIC ONCOLOGY, Vol.10 (9), p.S694.

Smyth, E.C.Turner, N.Pearson, A.Peckitt, C.Chau, I.Watkins, D.Kilgour, E.Smith, N.R.Gillbanks, A.Chua, S.Brown, G.Cutts, R.Rooney, C.Llavero, N.T.Thomas, A.Popat, S.Cunningham, D. (2015). Phase II study of AZD4547 in FGFR amplified tumours: gastroesophageal cancer (GC) cohort clinical and translational results, ANNALS OF ONCOLOGY, Vol.26, p.44.

Smyth, E.C.Turner, N.C.Peckitt, C.Pearson, A.Brown, G.Chua, S.Gillbanks, A.Johnston, S.R.TARAZONA, N.Cutts, R.Kilgour, E.Rooney, C.Smith, N.R.Sumpter, K.A.Ajaz, M.A.Thomas, A.L.Watkins, D.Chau, I.Popat, S.Cunningham, D. (2015). Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours., Journal of Clinical Oncology, Vol.33 (15_suppl), p.2508.

Gadgeel, S.M.Dols, M.C.Felip, E.Soria, J.-.Lee, K.H.Lu, S.Georgoulias, V.Fulop, A.Goker, E.Syrigos, K.N.Morabito, A.Coskun, H.S.Guclu, S.Z.Li, W.Popat, S.Ardizzoni, A.Lungershausen, J.Wang, B.Chand, V.K.Goss, G.D.Investigators, L.-. (2015). Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Patient-reported outcome (PRO) data from the LUX-Lung 8 Phase III global trial., JOURNAL OF CLINICAL ONCOLOGY, Vol.33 (15).

Yang, J.C.Popat, S.Georgiou, P.Miyamoto, E.Isaacson, J.D.Wakelee, H.A. (2015). TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy., JOURNAL OF CLINICAL ONCOLOGY, Vol.33 (15).

Pender, A.Garcia-Murillas, I.de Castro, D.G.Popat, S.Downward, J. (2014). 13 Molecular profiling of non-small cell lung cancer (NSCLC) – the liquid biopsy comes of age, Lung Cancer, Vol.83, p.S5.

Fennell, D.Antonov, A.Martins, M.L.Popat, S.Ramalingam, S.S.Spicer, J.Vukovic, V.M.El-Hariry, I.Reichert, V.Rosell, R. (2014). Abstract 4657: Evaluation of genomic profiling in the GALAXY-1 (NCT01348126), a randomized Phase 2b study of ganetespib in combination with docetaxel versus docetaxel alone as second line therapy in patients with advanced NSCLC, Presented at Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA, Clinical Research (Excluding Clinical Trials), .

Freydina, D.V.Tay, A.Chudasama, D.Freidin, M.B.Nicholson, A.G.Rice, A.Montero-Fernandez, A.Popat, S.Anikin, V.Lim, E. (2014). 47 The ability of a filter-based antibody-independent approach to capture circulating tumour cells for the diagnosis of lung cancer, Lung Cancer, Vol.83, pp.S17-S18.

Rimner, A.Litvak, A.M.Detterbeck, F.C.Filosso, P.L.Bruce, P.Ahmad, U.Rajan, A.Popat, S.Huang, J.Riely, G.J. (2014). A SURVEY OF CURRENT CLINICAL MANAGEMENT OF THYMIC CARCINOMAS AMONG ITMIG PHYSICIANS, JOURNAL OF THORACIC ONCOLOGY, Vol.9 (10), pp.S235-S236.

Sequist, L.Wu, Y.Schuler, M.O'Byrne, K.Sebastian, M.Popat, S.Boyer, M.Mok, T.Yamamoto, N.Hirsh, V.Geater, S.L.Zhou, C.Massey, D.Zazulina, V.Jones, H.Yang, J. (2014). Overall Survival (OS) With Afatinib Versus Chemotherapy in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring Common (Del19/L858R) Epidermal Growth Factor Receptor Mutations (EGFR Mut): Results of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6), International Journal of Radiation Oncology*Biology*Physics, Vol.90 (5), pp.S5-S6.

Lim, E.K.Freidin, M.B.Freydina, D.V.Chudasama, D.Leung, M.Popat, S.Gonzalez de Castro, D.Rice, A.Anikin, V.Montero Fernandez, A.Nicholson, A.G. (2014). A comparative study of blood-based KRAS mutation analysis in circulating tumor cells versus circulating plasma DNA to predict primary tumor mutations in lung cancer., Journal of Clinical Oncology, Vol.32 (15_suppl), p.7563.

Scagliotti, G.V.Leighl, N.B.Nowak, A.K.Pavlakis, N.Popat, S.Sorensen, J.B.Barrueco, J.Kaiser, R.Loembe, A.-.Mueller, M.von Wangenheim, U.Reck, M. (2014). Nintedanib plus pemetrexed/cisplatin followed by maintenance nintedanib for unresectable malignant pleural mesothelioma (MPM): An international, multicenter, randomized, double-blind, placebo-controlled phase II study., Journal of Clinical Oncology, Vol.32 (15_suppl), p.TPS7612.

Lu, S.Popat, S.Puglisi, M.Kaudeer, N.Gennatas, S.Hewish, M.Ayite, B.Bhosle, J.O'Brien, M. (2013). Phase 1b study of capecitabine and erlotinib in advanced non-small cell lung cancer, EUROPEAN JOURNAL OF CANCER, Vol.49, p.S828.

Freidin, M.B.Mair, D.Tay, A.Freydina, D.V.Chudasama, D.Popat, S.Nicholson, A.G.Rice, A.Montero-Fernandez, A.Anikin, V.De Castro, D.G.Lim, E. (2013). THE EFFICIENCY OF DETECTION OF KRAS, EGFR AND BRAF MUTATIONS IN PRIMARY LUNG CANCER VIA PERIPHERAL BLOOD CIRCULATING TUMOUR CELLS, JOURNAL OF THORACIC ONCOLOGY, Vol.8, p.S456.

Smyth, E.C.Turner, N.C.Popat, S.Morgan, S.Owen, K.Gillbanks, A.Jain, V.K.Cunningham, D. (2013). FGFR: Proof-of-concept study of AZD4547 in patients with FGFR1 or FGFR2 amplified tumours., JOURNAL OF CLINICAL ONCOLOGY, Vol.31 (15).

Popat, S. (2012). LARGE CELL NEUROENDOCRINE CARCINOMA: HOW SHOULD IT BE TREATED?, JOURNAL OF THORACIC ONCOLOGY, Vol.7 (6), p.S18.

Papa, S.Popat, S.Shah, R.McLennan, B.Lal, R.Lang-Lazdunski, L.Marsden, P.Viney, Z.Landau, D.Spicer, J. (2012). A PHASE 2 STUDY OF SORAFENIB AFTER FIRST LINE PLATINUM CONTAINING COMBINATION CHEMOTHERAPY IN MALIGNANT MESOTHELIOMA, JOURNAL OF THORACIC ONCOLOGY, Vol.7 (6), p.S84.

Twelves, C.Chmielowska, E.Havel, L.Popat, S.Swieboda-Sadlej, A.Sawrycki, P.Bycott, P.Niethammer, A.De Besi, P.Schiller, J.H. (2012). RANDOMISED PHASE II STUDY OF AXITINIB OR BEVACIZUMAB COMBINED WITH PACLITAXEL/CARBOPLATIN (PAC/CARB) AS FIRST-LINE THERAPY FOR PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC), ANNALS OF ONCOLOGY, Vol.23, p.409.

O'Brien, M.Gaafar, R.M.Popat, S.Grossi, F.Price, A.Talbot, D.C.Cufer, T.Ottensmeier, C.H.Danson, S.Pallis, A.G.Hasan, B.Van Meerbeeck, J.P.Baas, P. (2012). Phase II study of bortezomib with cisplatin as first-line treatment of malignant pleural mesothelioma (MPM): EORTC 08052, JOURNAL OF CLINICAL ONCOLOGY, Vol.30 (15).

Faria, A.Myerson, J.S.Puglisi, M.Starling, N.Ashley, S.Popat, S.O'Brien, M.E. (2009). 9062 The value of day 8 blood count in treatment decisions when using oral vinorelbine in non-small cell lung cancer (NSCLC) patients, European Journal of Cancer Supplements, Vol.7 (2), pp.523-524.

Trani, L.Myerson, J.Young, K.Sheri, A.Hubner, R.Puglisi, M.Popat, S.O'Brien, M.E. (2009). 9054 Histology classification is not a predictor of clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine or gemcitabine combinations, European Journal of Cancer Supplements, Vol.7 (2), p.521.

Rigual, N.R.Cheney, R.T.Iwenofu, O.H.Li, Q.Loree, T.R.Popat, S.R.Merzianu, M. (2007). Idiosyncrasies of Scalp Melanoma, The Laryngoscope, Vol.117 (8), pp.1354-1358.

Chandler, I.P.Popat, S.Pan, H.Zhao, D.Shao, Y.Chen, Z.Houlston, R.S. (2006). A prospective study confirms mismatch repair status predicts outcome in colorectal cancer, Presented at 190th Meeting of the Pathological-Society-of-Great-Britain-and-Ireland, Manchester, ENGLAND. JOURNAL OF PATHOLOGY, Vol.210, p.7.

Popat, S.Pan, H.Shao, Y.Zhao, D.Chen, Z.Houlston, R.S. (2005). A prospective blinded study of microsatellite instability (MSI) as a marker of overall survival (OS) in the adjuvant treatment of colorectal cancer (CRC) patients., Presented at 41st Annual Meeting of the American-Society-of-Clinical-Oncology, Orlando, FL. JOURNAL OF CLINICAL ONCOLOGY, Vol.23 (16), p.847S.

Sirohi, B.Matakidou, A.Ashley, S.Popat, S.Saka, W.Priest, K.Norton, A.James, M.Benepal, T.Eisen, T.O'Brien, M. (2005). Early response to platinum-based chemotherapy in non small cell lung cancer (NSCLC) predicts survival., JOURNAL OF CLINICAL ONCOLOGY, Vol.23 (16), p.672S.

Yau, T.Ashley, S.Popat, S.Norton, A.Matakidou, A.Priest, K.James, M.O'Brien, M.E. (2005). Case-control study comparing the cisplatin-based chemotherapy toxicity between elderly (age >/=70) and younger patient with lung cancer., JOURNAL OF CLINICAL ONCOLOGY, Vol.23 (16), p.680S.

Yau, T.Ashley, S.Popat, S.Norton, A.Matakidou, A.O'Brien, M. (2005). P-596 Chemotherapy treatments outcome and toxicities in the treatmentof elderly patients (age ⩾ 70) with lung cancer, Lung Cancer, Vol.49, p.S275.

Sirohi, B.Matakidou, A.Benson, C.Ashley, S.Priest, K.Norton, A.James, M.Saka, W.Popat, S.O'Brien, M. (2005). PD-082 Early response to platinum-based chemotherapy in nonsmall cell lung cancer (NSCLC) predicts survival unluike in mesotheliomas, Lung Cancer, Vol.49, p.S91.

Popat, S.Hubner, R.Houlston, R.S. (2004). A meta-analysis of microsatellite instability and colorectal cancer prognosis., Presented at 40th Annual Meeting of the American-Society-of-Clinical-Oncology, New Orleans, LA. JOURNAL OF CLINICAL ONCOLOGY, Vol.22 (14), p.853S.

Andreopoulou, E.Ross, P.J.O'Brien, M.E.Norton, A.Priest, K.Ashley, S.Popat, S.Harper-Wynne, C.Sumpter, K.Smith, I.E. (2003). The use of MVP chemotherapy in malignant mesothelioma: Outcome and predictive factors, BRITISH JOURNAL OF CANCER, Vol.88, p.S22.

Types of Publications

Journal Articles

Book Chapters

Conferences

In this section